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Abstract

The Hsp70 family of molecular chaperones is essential for
protein folding, re-folding misfolded client proteins, clearance of
aberrant client proteins, and can also inhibit programmed cell death.
There are two major cytosolic members of this family: the constitutive
Hsc70, and the inducible Hsp72.

Under stress conditions the Hsp70

family protects the cell from protein related damage by the induction
of Hsp72. Hsc70 and Hsp72 are highly homologous with minor
differences in substrate binding. In cancers, Hsp72 is commonly
induced and this induction is thought to aid in cancer cell survival. In
these studies we demonstrate the differential regulation of the prosurvival kinase Akt by Hsc70 and Hsp72. We demonstrate that of the
two cytosolic forms, Hsp72 is the primary Akt regulator. Using a
phenothiazine class inhibitor of Hsp70-family activity, methylene blue,
we demonstrate dose dependent decreases in the levels of Akt;
produced breast cancer specific cell death. This cell death could be
rescued by the use of an Hsp70 family ATPase stimulating compound,
SW02. We also demonstrate a similar phenotype with a rhodacyanine
vi

class Hsp70 family inhibitor, YM-1, also capable of reducing Akt and
causing cancer specific cytotoxicity. The resulting Akt decreases were
sufficient to block a tamoxifen-resistance pathway, allowing previously
resistant cells to regain sensitivity to tamoxifen. These results
demonstrate the capabilities of Hsp70 family inhibitors as potent
compounds for the treatment of breast cancer.

vii

Chapter 1:

Introduction

Breast Cancer
Breast cancers are among the most diagnosed cancers in women
(DeSantis et al., 2011). As with most cancers, there is no one cause
for tumorigenesis across all patients. Though little is known about the
initiating factors of breast cancer, these cancers often share similar
aberrant growth and survival pathways. However, there are numerous
pathways involved in the growth and survival of cancers. Some of
these pathways have already been targeted by therapeutics. However,
there are few therapies that can effectively target all varieties and
variations of breast cancer as there are few targets or pathway
elements that are common across multiple survival systems.
One of these commonalities is the expression of estrogen
receptor (ER) α, or lack-there-of. Approximately 75% of breast
cancers express estrogen receptor (Miller et al., 2011). Estrogen
dependent growth can be targeted with therapeutics. Antagonizing
ligand binding to ER (tamoxifen), downregulating ER (fulvestrant), or
1

preventing the synthesis of estradiol (aromatase inhibitors) are all
strategies used to treat ER+ tumors (Miller et al., 2011). However,
these strategies are not perfect as more than 30% of patients with
ER+ breast cancers relapse within 15 years of tamoxifen therapy, and
17% of patients treated with aromatase inhibitors relapse within 9
years (EBCTCG, 2005; Forbes et al., 2008). While the exact nature of
these resistance mechanisms is still unknown, with some hypotheses
described later, one pathway is often implicated as a factor in these
resistances

(along

with

general

tumor

cell

survival),

the

phosphatidylinositol 3-kinase (PI3K) pathway.

Survival and Growth Factors
The PI3K pathway is activated by various growth factor receptor
tyrosine kinases and G-protein coupled receptors. This activation
prompts PI3K to phosphorylate phosphatidylinositol 4,5-bisphosphate
(PIP 2 ) to yield phosphatidylinositol 3,4,5-triphosphate (PIP 3 ) (Whitman
et al., 1988). The formation of PIP 3 recruits proteins containing a
unique domain known as the pleckstrin-homology (PH) domain to the
cell membrane where PIP 3 is located. Binding of PH domain-containing
proteins to PIP 3 cue the activation mechanisms for some PH proteins
(Marte and Downward, 1997).

2

One of these proteins, Akt (protein kinase B/Akt), is a major
cytosolic kinase capable of regulating numerous pathways. These Aktregulated pathways can control cell metabolism, growth, death, and
mobility (Yoeli-Lerner and Toker, 2006). Akt performs these abilities in
both normal and cancer cell alike. However, the aforementioned
aberrant pathways involved in breast cancer, along with the underlying
tumorigenic factor itself, often can lead to Akt dysfunction (She et al.,
2008). This dysfunction leads to enhanced cellular growth, metabolism
and mobility; all while preventing cell death. This is the phenotype of
most cancer cells. In these cases, a cell cannot undergo the preprogrammed cell death pathways that should have been triggered to
prevent the cancer cell formation. Akt is at the center of this death
prevention while simultaneously causing the cells to grow out of
control.
Targeting Akt as with therapeutics appears to be promising, from
a distance. The Akt family of kinses is comprised of three members:
Akt1 (PKBα), Akt2 (PKBß), and Akt3 (PKBγ) (reviewed in Dillon et al.,
2007). Of these members, Akt1 and Akt2 are highly involved in the
growth and death pathways of tumor cells (Heron-Milhavet et al.,
2011). Akt1 and Akt2 exhibit a high degree of homology with some
redundancy;

though

recent

work

has

identified

complementary

opposing functions between these two members (Heron-Milhavet et
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al., 2011; Maroulakou et al., 2008; Maroulakou et al., 2007). This
redundancy is one of the two main reasons targeting Akt has proved
difficult in that removal of one variant does not block the systems
regulated by Akt. The other main hurdle is the inhibitory abilities
balanced between Akt1 and Akt2. Akt1 has been shown to play an
important role in breast cancer induction, whereas Akt2 promotes
migration of cancer cells. (Hutchinson et al., 2001; Hutchinson et al.,
2004). However, Akt1 has been shown to inhibit the migratory
regulation of Akt2, such that when Akt1 is silenced or specifically
inhibited tumor cells are more migratory (Dillon et al., 2009). A similar
phenomena occurs when targeting or silencing Akt2. Akt2 slows the
ability of Akt1 to regulate tumor growth; thus silencing or inhibiting
Akt2 leads to enhanced tumor growth, due to Akt1 (Dillon and Muller,
2010).

For

these

reasons,

individual

inhibitors

to

specific

Akt

members, again, fail to offer relief to multiple pathogenic factors.
Targeting total Akt might be a plausible strategy.
Again, Akt is activated through the PH domain interaction with
PIP 3 . Mutations found in this domain, in PI3K, or deletion of
phosphatase

and

tensin

homologue

(PTEN

-

the

the

phosphatase

responsible for the reversion of PIP 3 to PIP 2 ) can cause all Akt
members to become constitutively active (Carnero, 2010). As the PI3K
pathway is the most frequently altered pathway in breast cancer
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(Miller et al., 2011), inhibitors to PI3K have been identified. While
these compounds have demonstrated efficacy both in the lab and in
clinical trials (Liu et al., 2009) they only alter one specific pathway
which promotes aberrant Akt activity. To identify new therapeutics
that can regulate all Akt members, we would have to look beyond
targets that regulate Akt activity. We would need to alter the stability
of Akt to then prevent the genesis of aberrant Akt.

Molecular Chaperones
Molecular chaperones serve as the protein quality control
system. These chaperones identify improperly folded or denatured
proteins. These “misfolded” proteins are refolded or degraded to
prevent damage to the cellular environment (Kampinga and Craig,
2010). Chaperones are also responsible for the initial folding of some
proteins.

These

newly

transcribed

genes

require

chaperone

interactions immediately during translation. Other proteins often
interact with chaperones spanning the entire term of existence. All of
these proteins, commonly termed ‘clients’, are often sensitive to
changes in the chaperone network as their stability is dependent on
the activity of these chaperones.
Akt is a well documented client of the chaperone system. Work
conducted by our lab elucidated the mechanisms for Akt degraded by

5

chaperone

manipulation

(Dickey

et

al.,

2008).

However,

the

mechanisms used to facilitate this degradation, though used as a
cancer therapy, are not an ideal strategy for treating cancers; as will
be discussed.
The molecular chaperone system is comprised of several large
families of chaperones. Work from our lab detailed the role of the 90kDa heat shock proteins (Hsp90) in regulating Akt. Hsp90 is a known
regulator of multiple client proteins and is often implicated as having a
role in the pathogenesis of a number of maladies. Our work detailed
the use of Hsp90 inhibitors; compounds which inhibit the hydrolysis of
adenosine tri-phosphate (ATP) by Hsp90, a process necessary for
Hsp90 activity. This inhibition promotes Akt degradation via a ubiquitin
ligase known as CHIP (carboxy-terminus of Hsc70 interacting protein).
CHIP ligates ubiquitin to client proteins which are to be degraded by
the proteasome. This is a common degradation mechanism for
misfolded or aberrant proteins.
Similar to Hsp90, the 70-kDa heat shock protein (Hsp70) family
is involved in Akt stability. Hsp70 family members are ubiquitously
expressed through out all tissues with specific varieties targeted to
select organelles (Daugaard et al., 2007; Kampinga and Craig, 2010).
Hsp70 has two major members in the cytosol, Hsc70 (Hsp73) and
Hsp70 (Hsp72). Hsc70 is expressed across all tissues and is known as

6

the constitutive member of the cytosolic Hsp70 members. Hsp70 is the
stress inducible form of the cytosolic Hsp70 members. Under stress,
originally heat as the moniker indicates, a stress factor, HSF (heat
shock factor) is released from the constitutive chaperones. HSF
translocates to the nucleus where it binds the heat-shock-element
promoting the transcription of the inducible heat shock proteins,
namely Hsp70. This induction is how cells prevent total loss of function
under high heat conditions. Heat will denature tertiary protein
structure. Chaperones refold the denatured proteins, stabilizing the
once lost tertiary structure.

Stress and the Cancer Cell
A cancer cell is a stressed cell. Often, this stress causes cancer
cells to have elevated levels of Hsp70. In cancer, Hsp70 has been
shown to act in an anti-apoptotic capacity; this along side the cancer
cells need for protein homeostasis under stress (Sherman and
Multhoff, 2007). This anti-apoptotic action is through the interaction of
Hsp70 with pro-death proteins such as Smac/DIABLO and the
caspases (Dudeja et al., 2009; Jiang et al., 2009; Rashmi et al.,
2004). Smac/DIABLO and the caspases can be activated to drive
apoptosis through, among other initiators, mitochondrial damage
(Chen and Huerta, 2009; Galluzzi et al., 2006). Hsp70, in the instance
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of Smac/DIABLO activation, was shown to inhibit the activity of
Smac/DIABLO

following

mitochondrial

damage,

thus

preventing

apoptosis (Jiang et al., 2009).
There is evidence suggesting Hsp70, and the constitutive Hsc70,
play a role in regulating Akt (Shiota et al., 2010). Hsc70 has been
shown to interact with the PH domain; and in a certain instance inhibit
the activity of that PH protein (Kauppinen et al., 2005). Also, our
group identified that CHIP is the ubiquitin ligase necessary for Akt
degradation following Hsp90 inhibition (Dickey et al., 2008). CHIP was
originally identified as an interacting partner of Hsc70 (Ballinger et al.,
1999). These findings coupled with the induction of Hsp70, a robust
increase in levels due to HSF release from Hsp90, following inhibition
of Hsp90 (Zou et al., 1998) suggest that the cytosolic Hsp70 family
members are highly involved in Akt stability.

Hsp70 Inhibitors
As mentioned, Hsp90 inhibitors clear Akt by promoting the
degradation of Akt by the proteasome. This occurs via ubiquitination
regulated by the ubiquitin ligase CHIP. While Hsp90 inhibitors are in
clinical trials for the treatment of numerous cancers (Pacey et al.,
2010; Pacey et al., 2011; Rajan et al., 2011) and can clear total Akt
(Dickey et al., 2008), the induction of the anti-apoptotic Hsp70
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consistently observed following Hsp90 inhibition (so consistently, that
measuring Hsp70 levels is often used as a marker to identify a
successful Hsp90 inhibitor (Powers and Workman, 2007)) could reduce
the efficacy of Hsp90 inhibitors as cancer therapeutics since Hsp72
induction can act to inhibit cell death. This demonstrates the potential
for why Hsp70 should be the target of inhibitors. Some cancer cells
have shown sensitivity to silencing of Hsp72 by siRNA (Wei et al.,
1995). It has also been shown that dual silencing of Hsc70 with Hsp72
yields cell death (Powers et al., 2008).
We have conducted work with multiple chemical scaffolds
designed to inhibit the ATPase activity of the cytosolic Hsp70 family
members. These inhibitors were able to clear a pathogenic client of
Hsp70,

the

microtubule-associated

neurodegenerative

factor

of

protein

Alzheimer’s

τ

disease

(MAPT/tau)
(Jinwal

et

a
al.,

2009)(see also Appendices A and B for more information on the
regulation of tau by the co/chaperone network). Interestingly, Akt and
tau were found to compete for the same degradation machinery and
Hsp90 inhibition has the same effect on both clients (Dickey et al.,
2008). Thus, Hsp70 inhibition could reduce the levels of Akt while
preventing the anti-apoptotic abilities observed with Hsp70. To study
this mechanism we will also utilize compounds which stimulate the
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ATPase activity of Hsp70. These compounds should produce an effect
opposite to the ATPase inhibitors.
Inhibiting the ATPase activity of Hsp70 locks Hsp70 into a
conformation that allows neither the release of a bound client nor can
Hsp70 interact with a new client. This substrate blockade is regulated
by the C-terminal “lid” for the substrate binding domain. ATP is
hydrolyzed to ADP in the N-terminal ATPase domain of Hsp70. This
hydrolysis drives the closing of the “lid” to the high affinity state.
Release of substrate, via “lid” opening, is achieved by the replacing of
ADP with ATP in the nucleotide binding domain (reviewed in Daugaard
et al., 2007; Kampinga and Craig, 2010). This exchange is facilitated
by nucleotide exchange factors which can be chaperones or cochaperones (Liberek et al., 1991).
The interaction of Hsp70 with PH domain containing proteins and
the observed interactions between Hsp70 and Akt (Gao and Newton,
2002) suggests that if the ATPase activity of Hsp70 is inhibited the
interaction between Hsp70 and Akt will be lost. If the interaction
between Akt and Hsp70 is required for Akt stability, the resulting loss
of stability could drive Akt degradation. A second possible mechanism
exists for these Hsp70 inhibitors. If these inhibitors block the exchange
of ADP for ATP, which could produce similar effects on an ATPase
assay as an actual ATPase inhibitor, then any substrate bound to
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Hsp70 at the instance of compound interaction would be locked with
Hsp70. Losing the ability to release a bound client could also likely
signal for the degradation of the bound client as well as the
degradation of the now non-functional Hsp70. While this is entirely
speculation, the degradation of the tau protein following Hsp70
inhibition suggests that one of these mechanisms is at work.

11

References
Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY et al (1999).
Identification of CHIP, a novel tetratricopeptide repeat-containing
protein that interacts with heat shock proteins and negatively
regulates chaperone functions. Mol Cell Biol 19: 4535-45.
Carnero A (2010). The PKB/AKT pathway in cancer. Curr Pharm Des
16: 34-44.
Chen DJ, Huerta S (2009). Smac mimetics as new cancer therapeutics.
Anticancer Drugs 20: 646-58.
Daugaard M, Rohde M, Jaattela M (2007). The heat shock protein 70
family: Highly homologous proteins with overlapping and distinct
functions. FEBS Lett 581: 3702-10.
DeSantis C, Siegel R, Bandi P, Jemal A (2011). Breast cancer statistics,
2011. CA Cancer J Clin 61: 409-18.
Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ et al
(2008). Akt and CHIP coregulate tau degradation through coordinated
interactions. Proc Natl Acad Sci U S A 105: 3622-7.
Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ
(2009). Akt1 and akt2 play distinct roles in the initiation and
metastatic phases of mammary tumor progression. Cancer Res 69:
5057-64.
Dillon RL, Muller WJ (2010). Distinct biological roles for the akt family
in mammary tumor progression. Cancer Res 70: 4260-4.
Dillon RL, White DE, Muller WJ (2007). The phosphatidyl inositol 3kinase signaling network: implications for human breast cancer.
Oncogene 26: 1338-45.
Dudeja V, Mujumdar N, Phillips P, Chugh R, Borja-Cacho D, Dawra RK
et al (2009). Heat shock protein 70 inhibits apoptosis in cancer cells
through simultaneous and independent mechanisms. Gastroenterology
136: 1772-82.
EBCTCG (2005). Effects of chemotherapy and hormonal therapy for
early breast cancer on recurrence and 15-year survival: an overview of
the randomised trials. Lancet 365: 1687-717.
12

Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008).
Effect of anastrozole and tamoxifen as adjuvant treatment for earlystage breast cancer: 100-month analysis of the ATAC trial. Lancet
Oncol 9: 45-53.
Galluzzi L, Larochette N, Zamzami N, Kroemer G (2006). Mitochondria
as therapeutic targets for cancer chemotherapy. Oncogene 25: 481230.
Gao T, Newton AC (2002). The turn motif is a phosphorylation switch
that regulates the binding of Hsp70 to protein kinase C. J Biol Chem
277: 31585-92.
Heron-Milhavet L, Khouya N, Fernandez A, Lamb NJ (2011). Akt1 and
Akt2: differentiating the aktion. Histol Histopathol 26: 651-62.
Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ (2001).
Activation of Akt (protein kinase B) in mammary epithelium provides a
critical cell survival signal required for tumor progression. Mol Cell Biol
21: 2203-12.
Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ (2004).
Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated
mammary tumorigenesis but suppresses tumor invasion. Cancer Res
64: 3171-8.
Jiang B, Wang K, Liang P, Xiao W, Wang H, Xiao X (2009). ATP-binding
domain of heat shock protein 70 is essential for its effects on the
inhibition of the release of the second mitochondria-derived activator
of caspase and apoptosis in C2C12 cells. FEBS J 276: 2615-24.
Jinwal UK, Miyata Y, Koren J, 3rd, Jones JR, Trotter JH, Chang L et al
(2009). Chemical manipulation of hsp70 ATPase activity regulates tau
stability. J Neurosci 29: 12079-88.
Kampinga HH, Craig EA (2010). The HSP70 chaperone machinery: J
proteins as drivers of functional specificity. Nat Rev Mol Cell Biol 11:
579-92.
Kauppinen KP, Duan F, Wels JI, Manor D (2005). Regulation of the Dbl
proto-oncogene by heat shock cognate protein 70 (Hsc70). J Biol
Chem 280: 21638-44.

13

Liberek K, Marszalek J, Ang D, Georgopoulos C, Zylicz M (1991).
Escherichia coli DnaJ and GrpE heat shock proteins jointly stimulate
ATPase activity of DnaK. Proc Natl Acad Sci U S A 88: 2874-8.
Liu P, Cheng H, Roberts TM, Zhao JJ (2009). Targeting the
phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:
627-44.
Maroulakou IG, Oemler W, Naber SP, Klebba I, Kuperwasser C, Tsichlis
PN (2008). Distinct roles of the three Akt isoforms in lactogenic
differentiation and involution. J Cell Physiol 217: 468-77.
Maroulakou IG, Oemler W, Naber SP, Tsichlis PN (2007). Akt1 ablation
inhibits, whereas Akt2 ablation accelerates, the development of
mammary adenocarcinomas in mouse mammary tumor virus (MMTV)ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res
67: 167-77.
Marte BM, Downward J (1997). PKB/Akt: connecting phosphoinositide
3-kinase to cell survival and beyond. Trends Biochem Sci 22: 355-8.
Miller TW, Balko JM, Arteaga CL (2011). Phosphatidylinositol 3-kinase
and antiestrogen resistance in breast cancer. J Clin Oncol 29: 445261.
Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S et al (2010). A
Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG,
tanespimycin) in patients with metastatic melanoma. Invest New
Drugs.
Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A
et al (2011). A phase I study of the heat shock protein 90 inhibitor
alvespimycin (17-DMAG) given intravenously to patients with
advanced solid tumors. Clin Cancer Res 17: 1561-70.
Powers MV, Clarke PA, Workman P (2008). Dual targeting of HSC70
and HSP72 inhibits HSP90 function and induces tumor-specific
apoptosis. Cancer Cell 14: 250-62.
Powers MV, Workman P (2007). Inhibitors of the heat shock response:
biology and pharmacology. FEBS Lett 581: 3758-69.
Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S et al
(2011). A Phase I Study of PF-04929113 (SNX-5422), an Orally
14

Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with
Refractory Solid Tumor Malignancies and Lymphomas. Clin Cancer Res
17: 6831-9.
Rashmi R, Kumar S, Karunagaran D (2004). Ectopic expression of
Hsp70 confers resistance and silencing its expression sensitizes human
colon cancer cells to curcumin-induced apoptosis. Carcinogenesis 25:
179-87.
She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR et al
(2008). Breast tumor cells with PI3K mutation or HER2 amplification
are selectively addicted to Akt signaling. PLoS One 3: e3065.
Sherman M, Multhoff G (2007). Heat shock proteins in cancer. Ann N Y
Acad Sci 1113: 192-201.
Shiota M, Kusakabe H, Izumi Y, Hikita Y, Nakao T, Funae Y et al
(2010). Heat shock cognate protein 70 is essential for Akt signaling in
endothelial function. Arterioscler Thromb Vasc Biol 30: 491-7.
Wei YQ, Zhao X, Kariya Y, Teshigawara K, Uchida A (1995). Inhibition
of proliferation and induction of apoptosis by abrogation of heat-shock
protein (HSP) 70 expression in tumor cells. Cancer Immunol
Immunother 40: 73-8.
Whitman M, Downes CP, Keeler M, Keller T, Cantley L (1988). Type I
phosphatidylinositol kinase makes a novel inositol phospholipid,
phosphatidylinositol-3-phosphate. Nature 332: 644-6.
Yoeli-Lerner M, Toker A (2006). Akt/PKB signaling in cancer: a function
in cell motility and invasion. Cell Cycle 5: 603-5.
Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R (1998). Repression
of heat shock transcription factor HSF1 activation by HSP90 (HSP90
complex) that forms a stress-sensitive complex with HSF1. Cell 94:
471-80.

15

Chapter 2 1:

Facilitating Akt clearance via manipulation of Hsp70 activity
and levels

Abstract
Members of the 70-kDa heat shock family can control and
manipulate a host of oncogenic client proteins. This role of Hsp70 in
both the folding and degradation of these client proteins makes it a
potential drug target for certain forms of cancer.

The phenothiazine

family of compounds, as well as the flavonoid, myricetin, was recently
shown to inhibit Hsp70-ATPase activity, while members of the
dihydropyrimidine family stimulated ATPase function.

Akt, a major

survival kinase, was found to be under the regulation of Hsp70 and
when the ATPase activity of Hsp70 was increased or decreased by
these compounds, Akt levels respectively followed. Also, increasing
Hsp70

levels concurrent

with

inhibition

1

of

its ATPase

function

Portions of this work were previously published (John Koren III, Umesh K. Jinwal, Ying Jin, John O’Leary,
Jeff R. Jones, Amelia G. Johnson, Laura J. Blair, Jose F. Abisambra, Lyra Chang, Yoshinari Miyata, Anna M.
Cheng, Jianping Guo, Jin Q. Cheng, Jason E. Gestwicki, & Chad A. Dickey. Journal of Biological Chemistry
2010 Jan 22;285(4):2498-505.) and are used with permissioin of the publisher.
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synergistically reduced Akt levels to a greater extent than either
manipulation alone, providing new insights about client fate decisions.
Akt reductions mediated by Hsp70 inhibitors were prevented when
Hsp70 expression was silenced with siRNA. Inhibiting Hsp70 ATPase
function produced cytotoxic events only in breast cancer cell lines
where Akt dysfunction was previously shown, suggesting therapeutic
specificity depending on the Hsp70 client profile. Thus increasing
Hsp70 levels combined with inhibiting its ATPase function may serve to
dramatically reduce Akt levels and facilitate cell death in certain types
of cancer.

Introduction
Heat shock proteins are the primary regulators of protein folding
and degradation in the cell. The ATPase activity of Hsp70 and Hsp90
variants serves as the hub whereby all other chaperones and
cochaperones act upon, either to facilitate recycling or clearance of
chaperone substrates, or clients. Much of the effort surrounding
chaperone research has focused on either altering the expression
levels of these heat shock proteins by activating the heat shock
transcription factor (HSF1) or by inhibiting the activity of Hsp90
(Grenert et al.; Zou et al.). Small molecules have been identified that
can produce either or both of these outcomes (Bagatell et al.; Sittler et

17

al.). However, despite its clear role in a number of diseases of aging,
very little emphasis has been placed on the enzymatic ATPase activity
of Hsp70.

To address this deficiency, we recently identified several

compounds that could either stimulate or inhibit Hsp70 ATPase
function without affecting its levels (Jinwal et al., 2009). These
compounds bind to Hsp70 allosterically, affecting the rate of ATP
consumption, which is tied to opening and closing of the protein lid
over the substrate binding domain. When ATP is converted to ADP, the
lid closes, preventing release of the client. When ADP is exchanged for
ATP, the lid opens and the client is released. We demonstrated that
Hsp70 inhibitors force this lid to stay open, while activators increase
the rate of lid opening and closing (Jinwal et al., 2009). With these
compounds defined, we are now able to compare the effects of
increasing Hsp70 expression levels with modulating its ATPase function
for distinct disease-related clients.
With this in mind, and based on previous findings that the prosurvival kinase, Akt, was a well-established substrate of the chaperone
network (Ballinger et al., 1999; Cyr et al., 2002; Dickey et al., 2006;
Qian et al., 2006), we contrasted the impact of both Hsp70 expression
and activity on Akt stability (Dai et al., 2003; Dickey et al., 2008; Min
et al., 2008).

Because kinases in general have traditionally been

viewed as Hsp90 clients, most of the existing literature has focused on
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this relationship; however, more recent work suggests that not only is
the heat shock-inducible form of Hsp70 (Hsp72) influencing cell
survival and Akt levels, but the constitutive variant, Hsc70, might also
be playing a role (Powers et al.). Interestingly, our investigations here
using a siRNA screening assay initially suggested that these two
extremely similar Hsp70 variants were having opposing activities on
Akt protein levels. This unexpected result led us to further explore the
relationship, and we have found that inducible Hsp70 is a critical
mediator of Akt proteostasis. Then, using our newly described Hsp70
inhibitors, we discovered a second mechanistic paradox between
Hsp70 levels and function. Lastly, we show that inhibiting Hsp70
ATPase function can rapidly and selectively kill cancer cells that are
dependent on Akt for survival. Together, these results provide new
mechanistic and therapeutic insights into the relationship between
chaperones and Akt.

Materials and Methods
Cell Lines
The Hs578T breast cancer cell line and the syngenic non-cancer
control Hs578Bst fibroblast line collected from the unaffected breast of
the same patient (Hackett et al., 1977) were obtained from ATCC. We
also utilized MDA-MB-231, MDA-MB-468, MDA-MB-361, MCF7 and
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MDA-MB-453 cells (Yang et al., 2004). HeLa cells were also obtained
ATCC.

Antibodies, Plasmids, siRNAs and Chemicals
Anti-Hsp70 and anti-Hsc70 antibodies were purchased from
Steressgen (Ann Arbor, MI) and Anti-Akt (total Akt - #9272) antibody
was purchased from Cell Signaling Technology and all were used at
1:1000 dilutions. Anti-actin antibody was obtained from Sigma Aldrich
(St. Louis, MO) and used at a 1:1000 dilution.

All antibodies were

diluted in 7% nonfat dry milk in TBS solution. CA-Akt plasmid is a
constitutively active, via myristolation, form of mouse Akt-1, was
provided by Ben Wolozin (Boston University, Boston). All siRNAs were
acquired from Qiagen and were previously described and characterized
at a 20nM final concentration (Dickey et al., 2007; Jinwal et al., 2009).
Methylene Blue was obtained from Fisher Scientific. Azure C, SW02,
115-7C and myricetin were previously described (Jinwal et al., 2009).
KNK-437 was obtained from Sigma Aldrich.

Cell Culture and Transfections
Hs578T and MCF-7cells were grown in DMEM containing 10%
FBS, 1% PenStrep (Gibco), and 0.01mg/mL bovine insulin (Sigma
Aldrich).

Hs578Bst cells were grown in HybriCare media (ATCC)
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containing 10% FBS, 1% PenStrep and 30ng/mL epidermal growth
factor (Sigma Aldrich). MDA-MB-468, MDA-MB-361 and MDA-MB453
cell were grown in DMEM containing 10% FBS and 1% PenStrep. HeLa
cells were grown in Opti-MEM media containing 10% FBS and 1%
PenStrep.

MDA-MB-231 and T47D cells were grown in RPMI 1640

media containing 10% FBS and 1% PenStrep.

SiRNA transfections

were performed using SilentFect (BioRad) and left to incubate for 48
hours before harvest or treatment; with the exception of the KNK-437
experiment where 100µM of the reagent was added 24 hours post
transfection.

Plasmid

transfections

were

performed

using

Lipofectamine 2000 (Invitrogen) using 1ug plasmid per reaction; cells
were left to incubate for 48 hours before harvest or drug treatment.

Protein Collection, Quantitation and Western Blotting
Supernatants of selected experiments were harvested using
MPER (Invitrogen) containing phosphatase inhibitor cocktail 1 and 2
(Sigma Aldrich) at 1:100, protease inhibitor cocktail set III at 1:100
(Calbiochem) and PMSF (Fisher BioReagents) at 1:100. Protein levels
of the lysates were measured using the Pierce BCA kit.

All proteins

were standardized following BCA in BupH modified PBS (Thermo).
Western blotting was performed by running SDS-PAGE, followed by
transfer, followed by probing with antibodies and visualization by ECL
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(SignaGen). Western Blot quantitation was performed using Scion
Image for Windows (Scion Corporation) version Alpha 4.0.3.2.

In-Cell Western (ICW)
SiRNA and SilentFect were mixed in serum free media at a ratio
of 20nM to 1µl and distributed into indicated wells. Suspended HeLa
cells were added to these mixtures and incubated for 72 hours. Media
was removed from adherent cells and an In-Cell Western assay was
performed as previously described (Dickey et al., 2005). Rabbit AntiAkt antibody (1:500 as determined from Figure C1) and Mouse
GAPDH antibody (1:1000) from BioDesign were incubated overnight.
Secondary antibodies labeled with near-infrared fluorophores were
applied at 1:500 (Anti-rabbit AlexaFluor 680 from Molecular Probes
and Anti-mouse IR800CW from Rockland). Plates were imaged using
the LiCor Odyssey system.

LDH Assay.
Breast cancer cell lines were plated in using their designated
medias, according to ATCC. Once cells reached ~95% confluency,
methylene blue or vehicle treatments were applied in fresh serum free
Opti-MEM (Invitrogen) media. 6 hours later, media was collected and
centrifuged to pellet dead cells. Supernatant was then added to 96-

22

well plate in triplicate along with reagents from Cytotox96 kit
(Promega) following the supplied protocol.

Results
Hsp70 and Hsc70 reciprocally affect Akt levels
Previous work from our lab and others suggested that Akt was
critically modulated by the chaperone network (Beliakoff and Whitesell,
2004; Dickey et al., 2008; Gao and Newton, 2002).

To determine

which chaperones and chaperone-related proteins were most effective
at regulating Akt stability we developed an ICW assay to screen
chaperone siRNAs in a standard HeLa cell line, which was selected for
its high transfection efficiency, high levels of endogenous Akt and
robust properties of adhesion and viability to withstand a semi-high
throughput procedure (i.e. multiple washing steps, shaking, etc.;
Figure C1). Using this system, we found that siRNAs for Hsp70 or
Hsc70 respectively increased or decreased endogenous Akt levels by
~30%. Akt siRNA resulted in ~75% knockdown. Both Hsp90 and CHIP
siRNA also caused reductions in Akt levels, although to a lesser extent
than Hsc70. Hsp27 siRNA also increased Akt levels. Neither Bag1 nor
HSF1 siRNA had any effect on endogenous Akt levels. Akt levels were
normalized to GAPDH and increases or decreases are shown as a
percentage of the non-silencing control (Figure 2.1A-D). These
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findings coupled with our hypothesis that the Hsp70 family of proteins
may be involved in Akt stability led us to further investigate their
relationship.

Hsc70 modulates Akt levels indirectly via Hsp70
To confirm our ICW results, we analyzed lysates from HeLa cells
transfected with either Hsc70 siRNA, Hsp70 siRNA or a non-silencing
control by Western blot. Akt levels confirmed the results from our ICW,
showing increased levels of Akt in the presence of Hsp70 siRNA and
decreased Akt levels in the presence of Hsc70 siRNA (Figure 2.2A).
Specific knockdown was confirmed for both siRNAs using Hsp and
Hsc70 antibodies. Interestingly, this analysis revealed that Hsp70
levels were increased when Hsc70 was knocked down, while Hsc70
levels seemed unaffected by Hsp70 knockdown. To probe this further,
we over-expressed Hsp or Hsc70 and explored not only the effects on
Akt, but also their effects on each other. Indeed, Hsp70 overexpression decreased Akt levels, while Hsc70 increased Akt levels,
reciprocal to the siRNA results (Figure 2.2B & C). Moreover,
increasing the level of Hsc70 decreased Hsp70 levels, again opposing
the results seen with siRNA. This suggested that the effects of Hsc70
on Akt were actually an indirect consequence of increasing Hsp70
expression. We considered two possible mechanisms for this; either
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Hsc70 was contributing to Hsp70 turnover, or it was regulating Hsp70
transcription. To test the latter, cells transfected with either Hsc70
siRNA or a non-silencing control were treated with vehicle or KNK-437,
a compound that inhibits heat shock transcription by blocking the
binding of HSF1 to heat shock elements (HSE) in Hsp promoters
(Ohnishi et al., 2004; Voyer and Heikkila, 2008; Yokota et al., 2000).
Western blot analysis showed that Akt clearance mediated by Hsc70
siRNA was blocked when Hsp70 transcription was inhibited, indicating
that Hsp70, not Hsc70, was critically linked to Akt stability (Figure
2.2D). Therefore we endeavored to further explore how Hsp70 might
be involved in fate decisions for Akt and what role, if any, this has in
altering cell viability.

Inhibition of Hsp70ATPase function reduces Akt levels
To determine whether Hsp70 levels and ATPase function could
converge to regulate Akt stability, we analyzed Akt levels in HeLa cells
following treatment with a group of recently identified Hsp70 ATPase
chemical modulators (Jinwal et al., 2009). Interestingly, Hsp70 ATPase
inhibitors (methylene blue (MB) and myricetin (Myr)) caused robust
decreases in Akt levels in a dose dependent manner (Figure 2.3A).
These

reductions

were

evident

within

1

hour

(Figure

2.3B).

Reductions were more pronounced over a 48 hour time course with
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MB; however, the flavonoid, Myr, lost activity after 24 hours (Figure
2.3C & D), likely due to the inherent instability of all flavonoid
compounds (Boulton et al., 1999). Because of the robust activity
demonstrated by MB, further studies defining the mechanisms involved
in Hsp70-mediated Akt clearance focused on this compound and its
demethylated derivative, Azure C (AC).

Activators of Hsp70 ATPase function facilitate Akt accumulation
From our previous chemical screening platform (Chang et al.,
2008; Jinwal et al., 2009), we not only identified inhibitors of Hsp70
ATPase function, but also activators. Therefore we tested the effects of
these dihydropyrimidine activators, SW02 and 1157C, on Akt levels in
HeLa cells. These activators, along with MB and AC, were incubated
with cells at two doses (10µM and 50µM) for 24hrs. Activation of
Hsp70 ATPase function with SW02 and 1157c increased Akt levels in a
dose dependent manner, relative to vehicle, while Hsp70 inhibition
with MB and AC reduced Akt levels (Figure 2.4A & B). Time course
analyses for 50µM doses of 1157C and SW02 showed accumulation of
Akt levels over time (Figure 2.4C & D). These results were somewhat
unexpected since Hsp70 over-expression caused a similar outcome for
Akt stability as did Hsp70 enzymatic inhibition, while Hsp70 activation
preserved Akt levels. One obvious explanation would be that the drugs
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are simply having off-target effects, which could not be over-looked
given that MB and Myr can both regulate mitochondrial respiration. To
address this issue, we investigated whether over-expression of Hsp70
combined with Hsp70 inhibition synergistically reduced Akt levels. A
dose response analysis was performed with MB and AC in cells
transfected with myc-tagged Hsp70 or empty vector. We indeed found
that while Hsp70 did decrease Akt levels, inhibition of Hsp70 ATPase
activity coupled with its over-expression was more effective than
either alone (Figure C2); however, this still did not definitively show
that MB and AC were working via Hsp70 to reduce Akt levels. There
was still a possibility that both manipulations were simply facilitating
Akt clearance through two distinct pathways.

Despite pluripotency, phenothiazines primarily affect Akt via Hsp70
modulation
To definitively address whether MB and AC were regulating Akt
levels by inhibiting Hsp70 ATPase function, we again turned to siRNA.
We suppressed Hsp70 expression in HeLa cells with Hsp70 siRNA and
performed a dose response study with MB. Indeed, Hsp70 siRNA
almost completely blocked MB-mediated decreases in Akt, relative to
cells transfected with a non-silencing control (Figure 2.5A & B).
Subsequent investigation of this phenomenon with both MB and AC
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showed that Hsp70, not Hsc70, was necessary for Hsp70-inhibitormediated Akt reductions (Figure 2.5C & D). In fact, Hsc70 siRNA
actually increased Hsp70 inhibitor efficacy, due to the increase in
Hsp70 levels caused by Hsc70 knockdown. Thus, Hsp70 overexpression and Hsp70 ATPase inhibition can converge to reduce the
pro-survival kinase Akt in cells. While paradoxical, these results can
actually be explained quite elegantly when considering the properties
of Hsp70 itself and our recent data with these compounds and the
microtubule associated protein tau ((Jinwal et al., 2009); see Figure
2.7 and the discussion for more detail regarding the model). One final
aspect of these studies was to test the potential therapeutic
application of these inhibitors in cancer cells whose survival is
dependent on high levels of Akt activity.

Phenothiazines selectively kill breast cancer cells
While heat shock proteins have traditionally been deemed
“protective” for cells, the results from our previous experiments
indicated that cancer cell lines, in which Akt has been found to be
critical for cell survival, may be uniquely sensitive to Hsp70 inhibition
with MB. We analyzed the effects of Hsp70 inhibition on cell survival
using 7 breast cancer lines. We emphasized the Hs578T cell line
because it has high levels of active Akt (Zhang et al., 2007), and we
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previously showed effects with CHIP and Hsp90 inhibitors in this line
(Dickey et al., 2008). We compared the effects of MB on the Hs578T
line with the Hs578Bst fibroblast line, which was isolated from the
opposite breast of the same patient. The effects of MB on the Hs578T
cells were dramatic; cells appeared morbid and non-adherent after
only 1hr of a 50µM MB treatment with nearly complete cell death after
24hrs. The Hs578Bst line on the other hand was completely unaffected
by treatment. We turned to LDH analysis to quantitatively show the
cytotoxicity. Cells were again treated with a 50µM concentration of MB
for 6 hours and LDH analysis showed double the amount of LDH in
spent media compared to that of the Hs578Bst media (Figure 2.6A).
We then investigated the effects of Hsp70 inhibition on additional
breast cancer cell lines with Akt dysfunction; MDA-MB-453, MDA-MB361, MCF7, MDA-MB-468, MDA-MB-231, MCF-7, T47D and MDA-MB361. Indeed, increased cytotoxicity was observed in each of these cell
lines to varying degrees, with the three estrogen receptor (+) cell lines
(MCF-7, T47D and MDA-MB-361) being the most affected (Figure
2.6B).

Since, we did not observe MB mediated toxicity in other

standard cell lines, such as HeLa and HEK293 (not shown), we
speculated that it was indeed Akt that was essential for survival in
these particular breast cancer cells. To test this, we over-expressed
constitutively active Akt (CA-Akt) in the Hs578T line, and performed a
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dose-response analysis with MB, again measuring LDH levels. We
found that at lower doses, Akt over-expression could abrogate
cytotoxicity

(Figure

2.6C)

despite

the

poor

DNA

transfection

efficiency of this cells line (only ~25% increase in expression). In fact,
the higher 25µM dose was able to override the low levels of CA-Akt.
We then made a second attempt to rescue the cytotoxic effects of
Hsp70 inhibition by pre-treating Hs578T cells with the Hsp70 ATPase
activator, SW02, 24 hours in advance of MB treatment. We found that
activating Hsp70 function prior to treating with an inhibitor completely
blocked the cytotoxicity previously seen at matching doses of MB
(Figure 2.6D). These data indicated that inhibition of Hsp70 by MB
could reduce Akt levels and kill specific cancer types that require Akt
for survival. Moreover, we were able to rescue these effects by overexpressing Akt or activating Hsp70 ATPase function.

Discussion
Here we have demonstrated for the first time that inhibition of
Hsp70 ATPase activity and Hsp70 over-expression can each facilitate
reductions in Akt stability. The ability of Hsp70 ATPase inhibitors to
promote Akt clearance was dependent on the levels of Hsp70 in the
cell. We also demonstrated that activating Hsp70 ATPase function
increases Akt levels. Moreover, using a newly developed ICW assay for
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analysis of siRNAs targeting important chaperones, we found that
Hsc70 and Hsp70 could differentially regulate Akt levels. Hsp27 siRNA
also appeared to increase Akt levels. In subsequent analyses, we
demonstrated that Akt reductions caused by Hsc70 siRNA were a direct
result of a compensatory increase in Hsp70 levels via heat shock factor
activation. We also demonstrate that certain breast cancer cell types
having high levels of active Akt may be susceptible to Hsp70 inhibition.
Ultimately, these studies suggest that Hsp70 is intimately involved
with Akt stability and modulating its levels and activity may be a
relevant therapeutic strategy for the treatment of breast cancer.
The most interesting aspect of this study is the initially
confounding result that Hsp70 over-expression and inhibition of its
activity could lead to the same outcome for Akt. In fact, based on our
preliminary data with Hsp70 over-expression, we initially speculated
that Hsp70 activators would decrease Akt levels, while inhibitors would
preserve it. However, these results, coupled with our findings with the
tau protein, suggest a mechanism that may change the way chaperone
biology is currently viewed. The mechanisms that facilitate the decision
of the Hsp70 complex to allow degradation or refolding a protein are
not known. It is only known that the rate of hydrolysis and turnover of
ATP can push the complex in either direction; more ATP consumption,
more refolding; less ATP consumption, more degradation. Our data
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here, when placed in the context of our recent findings with the tau
protein suggest an intriguing possibility: The nature of a specific client
along with the state of the cellular environment can be destructive or
productive. Some clients, like tau, may mostly be targeted for refolding. Therefore, tau levels are not dramatically reduced when Hsp70
levels are increased, because this only produces more pro-folding
Hsp70/tau complexes that are not degraded; however when we inhibit
the ATPase activity of Hsp70, this forces the release of tau from
Hsp70, leading to its degradation (Jinwal et al., 2009). Conversely,
because Hsp70 over-expression did reduce Akt levels, we would
speculate that Akt is typically targeted for degradation.

Then, when

we inhibit Hsp70 ATPase function, the remaining pool of Hsp70/Akt
complexes that was being targeted for re-folding is forced toward
degradation, leading to further decreases in Akt levels. This principle is
depicted graphically in Figure 2.7. Therefore, what initially seemed
paradoxical could actually shed new light on an area that is essential
for our complete understanding of the chaperone process; how Hsp70
and Hsp90 “decide” when to promote degradation or refolding by
accessory co-chaperones.
In addition to this interesting mechanistic insight, there are
logical comparisons with this work that could be drawn to Hsp90
inhibitors

(Workman,

2004).
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17-allyl-amino-17-

demethoxygelanamycin (17AAG), a specific Hsp90 ATPase inhibitor,
has shown efficacy for reducing cell survival proteins such as Akt
(Pelicano et al., 2006), propelling it to clinical trials as a potential
therapy for various cancers (Modi et al., 2007; Sharp and Workman,
2006; Yano et al., 1996). However, there seem to be several
important distinctions between Hsp70 and Hsp90 inhibition. For
example, since Hsp90 normally functions to bind HSF1 and prevent its
translocation to the nucleus (Bagatell et al., 2000), Hsp90 inhibition
induces a stress response while Hsp70 inhibition does not. In fact,
despite uncertainty about efficacy, this feature alone has prompted the
use of 17-AAG in breast cancer trials simply as a heat shock inducer
rather than an Hsp90 inhibitor (Ciocca et al., 1993; Gabai et al., 2009;
Munster et al., 2001; Vargas-Roig et al., 1997). In addition to this
major functional difference between Hsp70 and Hsp90, these proteins
also possess unique structures, binding partners and ATPase turnover
kinetics. Despite these critical differences, the line separating these
two proteins is often blurred when discussing the functional differences
between them. Perhaps now, with these tools at our disposal, we can
begin to further define the precise differences between Hsp70 and
Hsp90 function in a way that was not previously possible.
This notion of functional redundancy is even more common when
discussing Hsp70 and Hsc70, which often are used interchangeably in
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the literature. These proteins are extremely similar structurally, which
suggests they also have similar functions.

However, while these

proteins may function similarly at the biochemical level, as we and
others have shown, there are interesting differences between these
two proteins with regard to the role of Hsc70 in regulating Hsp70
expression. For example, silencing of Hsp70 increased levels of Her2
in SKBr3 cells while, Hsc70 silencing decreased these levels in the
same cell line (Havik and Bramham, 2007). Moreover, our data here
shows that Hsc70 is involved in Hsp70 expression, but not vice versa,
suggesting that Hsc70 is possibly a more dominant form. Perhaps
Hsp70 levels are partially regulated based on the existing levels of
Hsc70 (Havik and Bramham, 2007; Powers et al., 2008). It is Hsp70,
however, that appears to have the greater impact on Akt as seen by
the increases in Akt levels when Hsp70 is silenced and the decreases
in Akt when Hsp70 is induced or over-expressed. Hsc70’s activity on
Akt regulation appears to only exist via induction of Hsp70 expression.
It is important to note as well that the chemicals used in these studies
are not selective for Hsc70 or Hsp70; they do inhibit both enzymes
(Chang et al.). Despite this, Hsp70 levels are not affected by these
inhibitors (Figure 2.5), suggesting that the induction in Hsp70 caused
by Hsc70 siRNA is due to reduced levels of Hsc70, not activity. Thus,
Hsc70 and Hsp70 levels may be equally important for regulating Akt
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stability, but Hsp70 seems more likely to have a direct association with
this important kinase.
Another consideration from these studies is that both Akt and
Hsp70 have demonstrated pro-survival functions in certain cell types.
Recent evidence suggests that Hsp70 and Hsc70 play a role in
preventing apoptosis, a process in which Akt is also intimately
associated (Powers et al., 2008).

Hsp70 can bind to the apoptosis

precursor DIABLO (Smac) and the presence of a functional Hsp70
ATPase domain can prevent cell death (Jiang et al., 2009).

This

suggests that an induction of Hsp70, by any means, would potentially
be working against apoptosis. Therefore, at first glance, it is somewhat
counter-intuitive that Hsp70 over-expression and inhibition would both
lead to reductions in Akt levels, since Akt is known to promote cell
survival; this function would likely antagonize any anti-apoptotic
function of Hsp70. However, our results seem to point to a mechanism
whereby the oncogenic client repertoire involved in specific types of
cancer may be predictive of Hsp70 inhibitor efficacy: In other words, in
tumor cells that are dependent on Akt activation for transformation
and survival (similar to that found in the Hs578T line and the MDA-MB
lines), Hsp70 over-expression combined with Hsp70 inhibition may be
a very effective therapeutic strategy, simply because this would
eliminate more Akt; however, either strategy may be entirely
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ineffective, or even detrimental, in other types of cancer. This aspect
is

an

important

consideration

when

attempting

to

manipulate

oncogenic client proteins through modifications of the chaperone
network. Given the low toxicity profile of MB in humans, this strategy
could quickly move to the clinic for certain cancers based on client
composition. Knowing whether chaperone clients are contributing to
the initiation of oncogenic processes could be predictive of clinical
success with chaperone-based therapies.
Finally, it is important to consider that MB and Myr both are
pluripotent compounds, affecting mitochondrial function, as well as a
number of other processes in the cell (Kelner et al., 1988; Salaris et
al., 1991; Visarius et al., 1997). Therefore we cannot rule out that
these “non-Hsp70” effects are contributing to cell death; however, our
ability to rescue cell death by activating Hsp70 ATPase function
suggests that Hsp70 inhibition is a primary activity of MB and related
phenothiazine scaffolds, which is likely to prime certain cancer types
for death. While a therapeutic strategy involving Hsp70 for cancer
requires additional validation, as well as identification of more specific
compounds, our data support the idea that promoting Hsp70 levels
combined with inhibiting its activity is potentially an effective strategy
for reducing aberrant Akt levels in certain cancer types.
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Figure 2.1. Small scale siRNA screen reveals opposing effects of Hsp70 and
Hsc70 on Akt levels. HeLa cells were plated in 96-well plates at ~40% confluency
and transfected with indicated siRNAs for 72 hours. SiRNAs have been previously
validated by Western blot in this cell line. In-Cell Western analysis for Akt (A; Red)
and GAPDH (B; Green) showed ~30% increase in Akt levels when Hsp70 or Hsp27
was knocked down and as ~30% decrease in Akt levels when Hsc70 was knocked
down. Hsc70 siRNA decreased Akt levels most potently. An overlaid image of Akt
and GAPDH is presented for contrast (C). Triplicate wells were quantified and all
values are shown as a percent of control siRNA (Ctrl) after GAPDH normalization ±
SD (D).

43

Figure 2.2. Silencing and overexpression of Hsp70 and Hsc70 inversely
affect Akt and each other; effect is blocked by heat shock transcription
inhibition. HeLa cells, , were transfected with Hsp70 or Hsc70 siRNA or a nonsilencing control siRNA for 48 hours then analyzed by Western blot (20µg
protein/lane) (A). HeLa cells, at ~90% confluency, were transfected with Hsp70 and
Hsc70 expression vectors for 48 hours and analyzed by Western Blot (40µg
protein/lane) (B). Akt levels resulting from the overexpression of Hsp70 and Hsc70
data were quantitated ± SD (C). HeLa cells, at ~50% confluency, were transfected
with siRNA for Hsc70 or a non-silencing control; at the time of transfection, cells
were treated with either vehicle or 100µM heat shock element (HSE) inhibitor KNK437 for 48 hours; results were analyzed by Western Blot (20µg protein/lane) (D).
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Figure 2.3. Hsp70 ATPase inhibitors show reductions in Akt levels in HeLa
cells. Structure of methylene blue (MB) and myricetin (Myr) pictured at top. A 6hour dose response was performed with MB (A) or Myr (C) at indicated
concentrations in HeLa cells,. A time course of 50µM MB (B) or Myr (D) was also
performed at indicated time points in HeLa cells. 6 hour Myr dose response at
indicated dosages in HeLa cells, treated at ~90% confluency. All blots contained
20µg protein/lane.

45

Figure 2.4. Hsp70 ATPase activators display effects opposite those of
inhibitors. HeLa cells, at ~90% confluency, were treated for 24 hours with 10 and
50µM of Hsp70 ATPase inhibitors (MB or AC) or Hsp70 activators (SW02 or 115-7C)
and lysates were analyzed by Western blot (A). Quantitation was performed using
pixel density analysis and is shown as a percentage of vehicle treated cells ± SD ( inhibitor,
- activator) (B). HeLa cells, at ~90% confluency, were treated with
50µM doses of either SW02 or 115-7C and analyzed by Western blot (C).
Quantitation was performed using pixel density analysis and is shown as a
percentage of vehicle treated cells ± SD (
- 1157c,
- SW02) (D). All blots
contained 20µg protein/lane.
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Figure 2.5. Efficacy of Hsp70 ATPase inhibitors is dependant on levels of
Hsp70. HeLa cells, at ~50% confluency, were transfected with Hsp70 siRNA or a
non-silencing control (Ctrl) and were then treated with increasing doses of MB as
indicated. Lysates were analyzed by Western blot (A), and Akt levels as a percent of
vehicle ± SD following pixel density analysis ( - Hsp70 siRNA,
- Ctrl siRNA) (B).
HeLa cells, at ~50% confluency, were transfected with non-silencing siRNA (Ctrl),
Hsp70 siRNA or Hsc70 siRNA for 48 hours, and then were treated with 50µM MB, AC
or vehicle (C). Results were analyzed by Western blot and quantitation of Akt levels
by pixel density analysis is shown as a percentage of corresponding vehicle
treatments (grey bar – MB, black bar – AC) (D). All blots contained 20µg
protein/lane.
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Figure 2.6. Hsp70 inhibitors produce Akt-dependent cytotoxicity in breast
cancer cell lines. LDH assays were performed on media from Hs578Bst and Hs578T
cell lines, both at ~90% confluency, treated with 50µM MB or vehicle for 6 hours and
levels are shown as a percent of vehicle treated cells ± SD (A). LDH assays were
performed on media from MDA-MB-468, MDA-MB-231, MDA-MB-453, MCF-7, T47D,
and MDA-MB-361 cell lines, all at ~90% confluency, treated with 50µM MB or vehicle
for 6 hours. LDH levels are shown as a percent of vehicle treated cells ± SD and ER
expression (B). LDH assays were performed on media collected from Hs578T cells
transiently transfected at ~90% confluency with either a 6TR non-coding vector or a
myristolated Akt vector (CA-Akt) and treated with increasing dosages of MB or a
vehicle control for 6 hours. LDH levels are shown as a percent of cells overexpressing
CA-Akt relative to treatment matched 6TR control transfected cells ± SD. Inset
verifies Akt overexpression by pixel density analysis of western blot run on cells
receiving vehicle treatment (C). LDH assays were performed on Hs578T cells, at
~90% confluency, receiving a 24 hour 50µM dose of Hsp70 ATPase activator SW02
(gray bars) or vehicle (black bars) followed by 6 hour dose response treatment of
Hsp70 ATPase inhibitor MB or vehicle. LDH levels are shown as a percent of vehicle ±
SD (D). P values were determined by Student t-test. All blots contained 20µg
protein/lane.
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Figure 2.7. Model for targeting clients towards destructive or productive
pathways via Hsp70. As distinct clients (ex: Client 1 and Client 2) are bound by
Hsp70, there are two distinct fates which can emerge based on the client. These
fates can be classified as either pro-folding or pro-degradation. The biochemical
nature of the client bound to Hsp70 along with the state of the cellular environment
are the key factors which guide the Hsp70/client complex towards a fate: pro-folding
for those designated to be lead away from potentially non-productive mis-folding
pathways; or pro-degradation for those requiring turnover as indicated by internal
mechanisms. However, the exact mechanisms contributing to either of these
decisions are unknown. Increasing the levels of Hsp70 is more likely to decrease
certain clients while preserving others. By chemically modulating the ATPase activity
of Hsp70, we are able to dictate client fate. Hsp70 activators can promote the
accumulation of clients that would normally be degraded by Hsp70. Hsp70 inhibitors
can promote the degradation of clients that would normally be preserved. Thus
Hsp70 over-expression combined with Hsp70 inhibition would synergistically affect
clients that typically prefer degradation. Conversely, for clients that are more prone
to re-folding, over-expression of Hsp70 would have minimal impact on the levels of
these clients, but inhibition of Hsp70 ATPase function would cause reductions.
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Chapter 3 2:

Rhodacyanine MKT-077 Derivative, YM-1, Selectively Targets
Cancer Cells

Abstract
MKT-077, a rhodacyanine dye, was shown to produce cancer
specific cell death. However, complications prevented the use of this
compound beyond clinical trials. Here we describe YM-1, a derivative
of MKT-077. We found that YM-1 was more cytotoxic and localized
differently than both MKT-077 and methylene blue (MB). YM-1
demonstrated cytotoxicity across multiple cancer cell lines. The
obserrved toxicity was limited to cancer cell lines; immortalized cell
models were unaffected. This toxicity was thought to be Akt (Akt/PKB)
dependent as total Akt levels were reduced. These Akt reductions were
dependent on Hsp72. YM-1 failed to clear other known breast cancer
oncogenes as potently as the observed Akt clearance. The Akt

2

Portions of these results were previously published (John Koren III, Yoshinari Miyata, Janine Kiray, John
C. O’Leary III, Lana Nguyen, Jianping Guo, Laura J. Blair, Xioakai Li, Umesh K. Jinwal, Jin Q. Cheng, Jason
E. Gestwicki, Chad A. Dickey. PLoS One. 2012;7(4):e35566. Epub 2012) and are used with permission of
the publisher.
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clearance combined with the enhanced cytotoxicity demonstrates the
need to further study the rhodacyanine scaffold. Modifications to the
rhodacyanines could potentially be made to improve efficacy and
pharmacokinetic properties.

Introduction
MKT-077, a cationic rhodacyanine, has demonstrated cancer
specific toxicity and growth inhibition in vitro and in vivo across
multiple cancer varieties (Koya et al., 1996). It was determined that
MKT-077 localized to the mitochondria (Koya et al., 1996). MKT-077
entered into clinical trials for the treatment of advanced and refractory
solid tumors of various cellular origin, including: kidney, lung,
prostate, colon, adenocarcinomas, and melanomas (Britten et al.,
2000; Propper et al., 1999). The primary negative side effect observed
in both studies was renal toxicity (Britten et al., 2000; Propper et al.,
1999). The observed toxicity halted recruitment to one trial as similar
animal

studies

showed

irreversible

renal

toxicity

following

administration of MKT-077 (Britten et al., 2000; Propper et al., 1999).
Later it was discovered that MKT-077 interacted with mortalin (mot-2),
a 70-kda heat shock protein (Hsp70) family member, and that the
interaction of MKT-077 with mot-2 induced the release of the tumor
suppressor p53 from a complex with mot-2 (Wadhwa et al., 2000).
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This mot-2/p53 complex inactivated the tumor suppression abilities of
p53 by sequestering it in the cytosol in vivo (Wadhwa et al., 1998).
Breast cancers are among the most common cancers diagnosed
in women (DeSantis et al., 2011). Published data states that treating
MCF7 cells, a breast cancer cell model, with MKT-077 produces
cytotoxicity and alters growth (Britten et al., 2000; Koya et al., 1996).
However, in the results of two published Phase I clinical trials, no
patients with a solid breast tumor or refractory breast tumor were
included in the study (Britten et al., 2000; Propper et al., 1999).
In these data, we identify a functional derivative of MKT-077
that showed increased cytotoxicity across multiple cancer varieties
while still retaining the cancer specificity associated with MKT-077.
This enhanced activity was due to the intracellular localization of the
compound. One way in which these compounds are working is by
reducing total Akt levels. The rhodacyanine scaffold holds great
potential as a cancer therapeutic both as an individual treatment
strategy but also, potentially, as a combinational or synergistic option
for use with existing regimens.

Methods
Cell Lines
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The MCF7, HEK-293, M17, H4, MDA-MB-231, Hs578T and NIH3T3 cells were purchased from ATCC (Manassas, VA). HeLa cells were
generously provided by Dr. Kenneth E. Ugen at the University of South
Florida. He originally obtained them from ATCC (Manassas, VA).

Chemicals, Antibodies and siRNA
Methylene blue (MB) was purchased from Sigma Aldrich (St.
Louis, MO). MKT-077 and YM-1 were synthesized as described
(Kawakami et al., 1998). Anti-Akt1, Akt2, pAktS473, and RAS were
purchased from Cell Signaling Technology (Danvers, MA). Anti-ERα
and p53 were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-Actin was purchased from Sigma Aldrich. Anti-GAPDH was
purchased from Meridian Life Science (Memphis, TN). All siRNAs were
purchased from Qiagen and used as previously described (Koren et al.,
2010).

Cell Culture and Drug Treatments
MCF7, MDA-MB-231, Hs578T and HeLa cells were grown as
previously described (Koren et al., 2010). H4 and HEK-293 cells were
cultured in OPTI - modified Eagle’s medium (OPTI-MEM) from
Invitrogen supplemented with 10% fetal bovine serum (FBS) and 1%
PenStrep

(Invitrogen).

M17

cells
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were

cultured

in

OPTI-MEM

supplemented with 10% FBS, 1% PenStrep and 100mg/L Sodium
Pyruvate.

NIH-3T3 cells were cultured in DMEM with low-sodium

bicarbonate (1.5g/L) from ATCC supplemented with 10% FBS and 1%
PenStrep. MKT-077, YM-1, and MB were dissolved in DMSO. DMSO
was used as vehicle for MKT-077 and YM-1 where indicated. Exact
treatment strategies accompany data in results section.

Mitochondrial Isolation and Spectrophotometry
MCF7 cells were treated for 6 hours with vehicle (DMSO), MB,
YM-1, or MKT-077. Following treatment cells were harvested and
subcellular fractions collected using Pierce Mitochondrial Isolation Kit
from Thermo Scientific (Rockford, IL). Analysis of drug localization was
performed

by

spectroscopy

on

Thermo

Scientific

Nanodrop

spectrophotometer using the unique absorbance properties of the
three compounds. Concentrations and subsequent percentages were
approximated by generated concentration:absorbance curve (not
shown).

Protein Collection, Quantitation, and Western Blotting
Cells were harvested by application of mammalian protein
extraction reagent (Thermo) as previously described (Koren et al.,
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2010). Protein level measurement, equilibration, western blotting, and
detection were performed as previously described (Koren et al., 2010).

Lactate Dehydrogenase (LDH) Assay
Indicated cell lines were plated in designated medium. Once cells
reached ~95% confluency, MKT-077 or YM-1 was applied in DMEM
without phenol red. At times indicated per experiment, medium was
collected from each treatment and centrifuged to pellet dead cells and
debris. Protocol was followed as supplied from Cytotox-96 kit
(Promega).

Results
Improved Cytotoxicity of YM-1 Over Known Hsp70 Inhibitors
The cytotoxicity profiles of a series of derivatives to MKT-077 on
MCF7 cells were compared in a small-scale screen. The derivative YM-1
(Figure 3.1A) was found to have dose dependently toxicity levels
higher than MKT-077 after 24 hours (Figure 3.1B). We then
compared the toxicity of YM-1 with another Hsp70 inhibitor, methylene
blue (MB), a compound previously reported for producing cancer
specific toxicity (Koren et al., 2010). YM-1 demonstrated a higher dose
dependent toxicity than MB (Figure 3.1C).
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Altered Location of Action; Cancer Cell Specificity Maintained
One possible reason for this improved potency was cellular
localization. Taking advantage of the unique spectral properties of
these compounds, MCF7 cells were treated with MKT-077, YM-1 and
MB then fractionation of mitochondria from cytosol was performed.
Both MB and MKT-077 are known to localize to the mitochondria; thus
they can be utilized as controls (Gabrielli et al., 2004; Koya et al.,
1996). The subcellular fractions were analyzed by spectrophotometer
for the presence of the unique color prorties of each of the
compounds. These values were compared with a generated standard
curve of Abs:concentration (data not shown) to give an approximate
concentration of compound in each fraction and thus a percentage of
drug per location. Interestingly, YM-1, unlike MKT-077 was more
prevalent in the cytosolic fractions (Figure 3.2A).
Concerned that the lack of mitochondrial interaction would
reduce the cytotoxic specificity seen with rhodacyanines for cancer
cells, the selectivity of YM-1 on several cancer and immortalized cells
lines were tested. These included: Hs578T and MDA-MB-231 (breast
cancer), M17 (neuroblastoma), H4 (neuroglioma), HeLa (cervical
cancer), and two immortalized cell lines: HEK 293 (human embryonic
kidney) and NIH 3T3 (murine fibroblast). The cancer cell lines tested
all displayed toxicity following YM-1 administration; whereas, the two
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immortalized cell lines displayed minimal to no toxicity by LDH assay
(Figure 3.2B). This demonstrated that the cytosolic localization of
YM-1 did not affect its specificity for cancer cells.

YM-1 Reduces Akt Members; Greater Efficacy than Methylene Blue
Based on these results and our previous findings (Koren et al.,
2010), we speculated that the cytotoxicity observed in the breast
cancer cell lines was Akt-dependent. MCF7 cells were treated with YM1 (1, 3 and 10µM) for 6 hours, prior to onset of overt cytotoxicity
(data not shown). Lysates were analyzed by Western blot. Levels of
Akt1, Akt2, and Akt phosphorylated at S473, a site necessary for Akt
activity, were all reduced by YM-1 treatment (Figure 3.3A & B). The
effective concentrations were lower than those of

MB (Figure

3.3C)(Koren et al., 2010).

YM-1 Dependent on Hsp72 to Clear Akt; Does Not Clear Other
Oncogenes
We previously demonstrated that the reductions in Akt observed
following MB treatment were dependent on the levels of Hsp70 (Koren
et al., 2010). Thus, we conducted an experiment as performed
previously, silencing Hsp72 and treating with an Hsp70 inhibitor.
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Interestingly, the Akt reductions observed after YM-1 treatment were
dependent on Hsp72 levels; similar to MB (Figure 3.4A & B).
Given the role of the Hsp70 family in regulating a large number
of clients within the cell, we speculated that other oncoproteins might
be contributing to the phenotype produced by YM-1. Levels of p53,
Ras, and ERα were all assessed by Western blot. All changes in the
levels of these proteins were negligible compared to Akt (Figure 3.4C
& D). Thus, a major effect of YM-1 is to potently destabilize Akt,
suggesting that Akt is an especially sensitive client of the Hsp70 family
and the effects observed on cell viability are largely dependent on Akt
clearance.

Discussion
Here we describe the therapeutic potential of an MKT-077
derivative, YM-1. This compound, similar to MKT-077, was specifically
toxic to cancer cells. YM-1 also had greater efficacy and cytosolic
localization than MKT-077 and MB. YM-1 was able to reduce the levels
of Akt but not of other known oncoproteins; this via Hsp70 dependent
mechanisms.
It is possible that the cytosolic presence of YM-1, versus
mitochondrial of MKT-077, drives the increased toxicity and Akt
clearance observe with YM-1. Though the mitochondrial aspects of
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MKT-077 are well characterized (Britten et al., 2000; Koya et al.,
1996; Propper et al., 1999), recent data suggests that MKT-077 can
also interact with cytosolic Hsp70 family members (Rousaki et al.,
2011). If YM-1 is able to inhibit cytosolic Hsp70 as MKT-077 does
mortalin (Wadhwa et al., 2000; Wadhwa et al., 1998), the enhanced
efficacy of YM-1 could be due to this dual interaction. Hsp70 inhibitors
have demonstrated cancer specificity as well as the ability to reduce
Hsp70 client proteins (Jinwal et al., 2009; Koren et al., 2010; Leu et
al., 2009; Leu et al., 2011); thus we assume that the mode of action
for YM-1 is as a cytosolic Hsp70 inhibitor.
These studies demonstrate the need for more mechanistic
insight into the mode of action of rhodacyanines. Minor changes
between MKT-077 and YM-1 lead to an increased cytosolic presence
that was able to maintain similar specificity. This suggests that
modifications to this scaffold could elicit specific toxicity or reduce
renal toxicity, as observed in the clinical and laboratory trials (Britten
et al., 2000; Koya et al., 1996; Propper et al., 1999). In fact, our data
demonstrating an almost preferential killing of breast cancer cells,
versus other cancer cell types, suggests that specificity for particular
tumor varieties could be built into the rhodacyanine scaffold.
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Figure 3.1. MKT-077 derivative, YM-1, shows enhanced toxicity. Illustrated
structure of YM-1 (A). MCF7 cells were treated for 24 hours with three concentrations
of MKT-077 or YM-1. After 24 hours, medium was collected and analyzed by LDH
assay. Values shown are a % of vehicle treatment ± SD (B). MCF7 cells were treated
for 24 hours with three concentrations of MB or YM-1. After 24 hours, medium was
collected and analyzed by LDH assay. Values shown are a % of vehicle treatment ±
SD (C).
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Figure 3.2. YM-1 localization doesn’t alter cancer specific toxicity; noncancer cells unaffected. MCF7 cells were treated with MKT-077, YM-1 or
methylene blue (MB). Mitochondrial fractions were collected and compound location
was measured by spectrophotometer (A). Hs578T and MDA-MB-231 (breast cancer),
M17 (neuroblastoma), H4 (neuroglioma), and HeLa (cervical cancer) cell treated with
increasing concentrations of YM-1 and the toxicity was compared to NIH-3T3 (mouse
embryonic fibroblast) and HEK 293 (human embryonic kidney) cells for cancer
specific toxicity. All cell lines were treated for 24 hours. After 24 hours, media were
collected and analyzed by LDH assay. Values shown are a % of vehicle treatment ±
SD
(B).
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Figure 3.3. Akt members are concentration dependently reduced by YM-1;
dependent on Hsp70. MCF7 cells were treated with noted concentrations of YM-1
for 6 hours. Cells lysates were analyzed by Western blot (A). Densitometry analysis
of Akt-1, Akt2, and pAkt S473 levels shown as % of vehicle treatment ± SD (B).
Comparison of densitometry analysis between MB and YM-1 treatment-dependent
Akt reductions shown as % of vehicle treatment ± SD (C)
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Figure 3.4. Oncogenic factors less affected than Akt by YM-1 treatment.
MCF7 cells were treated with noted concentrations of YM-1 for 6 hours. Cells lysates
were analyzed by Western blot (A). Densitometry analysis of (total) Akt, ERα, p53,
and RAS levels shown as % of vehicle treatment ± SD (B).
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Chapter 4 3:

Overcoming Akt-dependent Tamoxifen Resistance by Inhibiting
Hsp70

Abstract
The

major

survival

kinase

Akt

can

regulate

numerous

tumorigenic and pro-survival pathways. These regulated pathways can
include mechanisms that can induce resistance to chemotherapeutics.
Thus, reducing Akt activity or levels is considered a promising anticancer

and

therapy

sensitization

strategy.

We

have

previously

demonstrated that inhibitors of the 70-kDa heat shock protein (Hsp70)
family can clear Akt. However, the potential impact of this activity on
regulating resistance was not clear. Here, we demonstrate that
treatment of tamoxifen resistant cells with an Hsp70 inhibitor, YM-1,
for only 4 hours restored tamoxifen sensitivity; likely through Akt
dependent mechanisms. The ability to restore tamoxifen sensitivity

3

Portions of these results were previously published (John Koren III, Yoshinari Miyata, Janine Kiray, John
C. O’Leary III, Lana Nguyen, Jianping Guo, Laura J. Blair, Xioakai Li, Umesh K. Jinwal, Jin Q. Cheng, Jason
E. Gestwicki, Chad A. Dickey. PLoS One. 2012;7(4):e35566. Epub 2012) and are used with permission of
the publisher.
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was due to a mechanism involving phosphorylation of estrogen
receptor. Conversely, an Hsp70 activator facilitated the emergence of
tamoxifen resistance in naïve cells. Together, these findings provide a
potential strategy for the treatment of standard and refractory cancer
types, which would be expected to have multiple clinical applications
for breast cancer.

Introduction
Breast cancers also have a high prevalence of mutations;
mutations which can promote tumorigenesis and survival (Hudis and
Gianni, 2011). While these mutations produce targets for treatments,
other mutations can overcome signaling cascade network circuitry to
eliminate upstream targets (Oliveira et al., 2005; Uray and Brown,
2011). This reduces the number of potential targets, reducing the
cadre of treatment options, and increasing the potential for resistance
genesis. In addition, resistance can emerge when regulatory proteins
are altered to allow pro-survival proteins to act unabated. Several
kinases related to cell survival have been implicated in facilitating
chemotherapy resistance (Brognard et al., 2001; Campbell et al.,
2001; Clark et al., 2002; Guo et al., 2010; Sun et al., 2001). Thus,
strategies to re-sensitize refractory cancer cells to existing therapies
are sorely needed.
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A majority of breast cancer patients have estrogen receptor
alpha (ERα)-positive tumorw which respond to anti-estrogen therapy
(Lin et al., 2010; McDonnell and Wardell, 2010; Rivera-Guevara and
Camacho, 2011; Shanle and Xu, 2011). The binding of estradiol, a
predominant estrogen, to ERα ultimately leads to the transcription of
pro-proliferation genes such as c-myc, cathepsin D, and transforming
growth

factor-α

(Nicholson

et

al.,

1999).

The

compound

4-

hydroxytamoxifen (4-OHT) or its pro-drug Tamoxifen is an ERα
antagonist that has been used to prevent the transcription of prosurvival genes (Rivera-Guevara and Camacho, 2011). However, the
emergence of resistance to 4-OHT in tumor cells diminishes the longterm efficacy of this approach (Katzenellenbogen et al., 1997). A
common cause for the emergence of 4-OHT refractory breast cancer is
post-translational modifications of ERα, particularly phosphorylation.
Specifically, a major regulator of cancer pathogenesis, Akt, often
facilitates 4-OHT-insensitivity in breast cancer cells by phosphorylating
ERα (Campbell et al., 2001; Lannigan, 2003; Park et al., 2008; Sun et
al., 2001; van Agthoven et al., 2009a; van Agthoven et al., 2009b).
Akt (protein kinase B, PKB/AKT) is a major regulator of the PI3K
signal transduction pathway, as well as a key pro-survival/antiapoptosis kinase (Cardone et al., 1998; Castaneda et al., 2010; Chen
et al., 2001; Kennedy et al., 1999; Kops et al., 1999; Romashkova
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and Makarov, 1999). Akt is often chronically activated in a variety of
cancers (Brognard et al., 2001; Campbell et al., 2001; Clark et al.,
2002; She et al., 2008; Sun et al., 2001), and it is associated with the
development of resistance to chemotherapeutics including TAM/4-OHT
and others (Brognard et al., 2001; Campbell et al., 2001; Clark et al.,
2002; Sun et al., 2001). Akt1 and Akt2 (PKBα and PKBβ) can each
phosphorylate ERα at Ser-167. This enhances ERα transcriptional
activity independent of estrogen binding, allowing tumor cells to grow
in the presence of this common therapeutic (Campbell et al., 2001;
Lannigan, 2003; Meijer et al., 2006; Park et al., 2008; Sun et al.,
2001; van Agthoven et al., 2009a; van Agthoven et al., 2009b) We
propose that reducing levels of total Akt, rather than selectively
targeting a single member, might not only be therapeutically beneficial
for certain types of cancers, but it may also be a plausible strategy for
restoring sensitivity to tumors that have developed resistance to
standard therapies.
One potential way to reduce the levels of Akt is to manipulate
the molecular chaperone system to promote Akt clearance. The family
of 70kDa heat shock proteins (Hsp70) represents a major portion of
the chaperone repertoire and it stabilizes a number of oncogenic client
proteins, including Akt (Gao and Newton, 2002; Koren et al., 2010;
Shiota et al., 2010). Phenothiazine compounds, such as methylene
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blue and azure C, are low potency Hsp70 inhibitors that generate
cytotoxicity in a number of breast cancer cell lines by depleting Akt
levels (Koren et al., 2010). As described in the previous chapter, the
rhodacyanine

YM-1

is

capable

of

total

Akt

reduction

and

at

concentrations lower than MB. These data provided a proof-of-concept
study: depletion of Akt levels based on Hsp70 modulation could be a
novel strategy for treating refractory breast cancers when aberrant Akt
activity is driving the resistance.
Here, we use YM-1; a compound previously shown to potently
and selectively reduce the protein levels of both Akt1 and Akt2. The
loss of Akt activity restored tamoxifen sensitivity in a previously
resistant cell model. These studies suggest possible therapeutic
approaches for successful implementation of this strategy in a clinical
setting.

Methods
Cell Lines
Tamoxifen resistant (TR-MCF7) and parental MCF7 cells were
generously provided by Dr. Jin Q. Cheng of Moffitt Cancer Center
(Tampa, FL).

Antibodies, siRNAs, and Chemicals
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Anti-ERα, and pERα S167 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-Actin was purchased from Sigma
Aldrich

(St. Louis,

MO). Anti-Hsp90ß (H90-10) was generously

provided by Marc B. Cox (University of Texas, El Paso). All siRNAs
were purchased from Qiagen and used as previously described (Koren
et al., 2010). SW02 was synthesized as previously described (Wisen et
al., 2008). YM-1 was synthesized as described (Kawakami et al.,
1998).

Cell Culture and Transfections
MCF7 cells were grown as previously described (Koren et al.,
2010).

TR-MCF7 cells were grown in DMEM (described with MCF7

cells) supplemented with 10µM 4-OHT. siRNA transfections were
performed using SilentFect (Bio-Rad) and incubated as directed for 48
h before harvest or treatment.

Protein Collection, Quantitation, and Western Blotting
Cells were harvested by application of mammalian protein
extraction reagent (Thermo) as previously described (Koren et al.,
2010). Protein level measurement, equilibration, western blotting, and
detection were performed as previously described (Koren et al., 2010).
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Lactate Dehydrogenase (LDH) Assay
Indicated cell lines were plated in designated medium. Once cells
reached ~95% confluency, YM-1 or vehicle was applied in fresh DMEM
without phenol red. At described times following application of
treatment condition, medium was collected from each treatment and
centrifuged to pellet dead cells and debris. Protocol was followed as
supplied from Cytotox-96 kit (Promega).

MTT Cell Viability Assay
TR-MCF7 cells were plated in a 96well plate in medium
containing 10µM 4-OHT. When cells reached ~90% confluency cells
were treated in OPTI-MEM in one of four conditions 1: DMSO (vehicle)
or varied concentrations of YM-1 for 48 h. 2: Vehicle or varied
concentrations of YM-1 for 4 h followed with exchange of YM-1
medium with 4-OHT medium. 3: Vehicle or varied concentrations of
YM-1 for 4 h followed with exchange of YM medium with medium
containing a vehicle treatment for 4-OHT (volume matched 95%
EtOH). Or, 4: 10µM 4-OHT in OPTI-MEM for the full 48 h of
experiment. MTT assay kit was purchased from ATCC and assay was
run as per supplied protocol.
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Cell Proliferation Assays
MCF7 cells were plated at 10,000cells/mL. 24 h after plating,
chemical compounds (vehicle or 50µM SW02) were applied to the cells
in OPTI-MEM. After 24 h incubation in SW02 or vehicle medium was
exchanged with medium containing 10µM 4-OHT. 48 h post 4-OHT
addition, medium was removed and cells were simultaneously fixed
and stained with a 0.1% crystal violet in 30% MeOH for 20 minutes.
Excess dye was washed off with water. 10% Acetic acid solution was
used to free the bound crystal violet. Absorbance of released crystal
violet was read at 570nm on NanoDrop spectrophotometer (Thermo).

Isolation of Nuclear Proteins
TR-MCF7 cells were grown in designated medium in 10cm
dishes. Cells were treated for 4 h with 10µM 4-OHT, 10µM YM-1, both
or vehicle(s) for both compounds. Following incubation, cells were
harvested and nuclear proteins isolated using reagents and supplied
protocol from the Qproteome Nuclear Protein Kit (Qiagen).
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Results
Limited Toxicity from Brief YM-1 Treatments
YM-1 efficacy was tested in a cell model of tamoxifen-resistance.
The toxicity of YM-1 in a refractory tamoxifen (4-OHT) resistant MCF7
(TR-MCF7) cell line was compared to that of the parental MCF7 (nonresistant) cell line. Indeed, YM-1 effectively killed both standard and
resistant (TR-MCF7) cells after 48-hour incubation (Figure 4.1A).
Given the previous concerns with chronic MKT-077 (the parent
compound of YM-1) treatment (Britten et al., 2000; Propper et al.,
1999), we speculated that a shorter treatment with YM-1 might be
equally toxic. To test this, MCF7 cells and TR-MCF7 cells were treated
with 10µM YM-1 for 4 hours. This was removed and replaced with
vehicle for 44 hours. In addition, TR-MCF7 cells were treated with
either 4-OHT or the vehicle for 4-OHT (95% EtOH) (Figure 4.1B). In
each case, minimal toxicity was observed.

Overcoming 4-OHT Resistance with YM-1
Cell viability (MTT) assays were then used to test whether this
shorter treatment strategy was affecting cell proliferation. The TRMCF7 cells were grown in media containing 10µM 4-OHT. Our designed
treatment strategy contained four conditions all terminating at 48
hours: 1. 10µM 4-OHT alone for 48 hours, 2. YM-1 (or vehicle)
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treatment for 4 hours followed by re-addition of 10µM 4-OHT for 44
hours, 3. YM-1 (or vehicle) treatment for 4 hours followed by 95%
EtOH (vehicle for 4-OHT), and 4. YM-1 (or vehicle) treatment for the
full 48-hours. MTT assays revealed that the 4-hour 10µM YM-1
followed by 10µM 4-OHT treatment reduced viability by 60% relative
to the 4-OHT treatment alone. The 10µM YM-1 followed by 95% EtOH
treatment did not alter viability (Figure 4.2A). The 48-hour 10µM YM1 treatment reduced viability by 40% compared to 48-hour 4-OHT
treatment, similar to Figure 4.1A.
All treatment strategies containing YM-1 were analyzed by twoway ANOVA (Figure 4.2B). This analysis revealed a significant effect
by treatment strategy and concentration of YM1 (F(4, 30)=41.04,
p<0.0001), (F(2,30)=54.22, p<0.0001). The interaction between
treatment

strategy

and

concentration

was

not

significant

(F(8,30)=1.83, p=0.1107). Bonferroni post-hoc analysis of this 2-way
ANOVA

showed

no

significant

differences

between

any

of the

concentrations used for the 48-hour YM-1 treatment and the 4-hour
YM-1 followed by 95% EtOH treatment (all p>0.05); whereas, all the
concentrations used for the 4-hour YM-1 followed by 4-OHT treatment
were significantly different from the 4-hour YM-1 followed by 95%
EtOH treatment (all p<0.05). All the concentrations of the 4-hour YM-1
followed by 4-OHT and the 48-hour YM-1 were significantly different
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(all p<0.05) with the exception of the 10µM YM-1 concentration
(p>0.05). We attributed the lack of significance to the general toxicity
caused by the 48-hour 10µM concentration of YM-1 (see Figure 4.1A
& B). A one-way ANOVA of the YM-1 concentration curve for the 4
hour YM-1 treatment followed by 44 hours of 4-OHT treatment
revealed that the 10µM concentration was significantly different from
all other concentrations (F(4,10)=16.49, p=0.0002)(Figure 4.2C).
The concentration curve for the 4 hour YM-1 treatment followed by
95% EtOH treatment displayed that no concentration was significant
from any other concentration by one-way ANOVA (F(4,10)=3.435,
p=0.0516)(Figure 4.2D). Comparison of all of the 48 hour YM-1
concentrations, by one-way ANOVA, displayed that, again, the 10µM
concentration was significantly different from all other concentrations
in this treatment (F(4,10)=12.32, p=0.0007)(Figure 4.2E). We
continued our analysis by comparing the 10µM YM-1 concentration,
from all treatment groups, with the null treatment. Viability values of
all aforementioned treatment conditions, with the inclusion of the 4OHT 48 hour treatment and vehicle treatments as separate groups,
were analyzed by one-way ANOVA (F,(5,12)=24.33, p<0.0001).
Tukey’s post-hoc test revealed that 4 hour YM-1 followed by 4-OHT
was significantly different from the 4-OHT 48 hours treatment
(p<0.05), whereas both the 48 hour 10µM YM-1 and the 4 hour 10µM
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YM-1 followed by 95% EtOH treatments were not significantly different
from the 4-OHT 48 hour treatment (Figure 4.2F). This analysis also
displayed that 10µM YM1 followed by 4-OHT is significantly different
from 10µM YM1 followed by 95% EtOH (p<0.05).

ERα Phosphorylated at Akt Consensus Site Reduced by Brief YM-1
Treatment
These findings suggested that just a 4 hour treatment of 10µM
YM-1 could re-sensitize TR-MCF7 cells to tamoxifen/4-OHT, stopping
cell growth without causing overt toxicity. The potential mechanisms
for this phenomenon were then explored.

One plausible mechanism

was aberrant kinase activity, which is known to promote tamoxifen
resistance by phosphorylating ERα at a site known to promote
estrogen independent activity (Brognard et al., 2001; Campbell et al.,
2001; Clark et al., 2002; Guo et al., 2010; Sun et al., 2001). We
treated TR-MCF7 cells as described for the experiments in Figure 4A &
B. Nuclear proteins were isolated and probed for levels of ERα pS167,
a site that when phosphorylated conveys tamoxifen independence.
Indeed, phosphorylation of ERα pS167 was elevated in the presence of
4-OHT; however, the addition of 10µM YM-1 abrogated this event
(Figure 4.3A & B). YM-1 did not alter the localization of ERα (Figure
4.3C & D).
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Hsp70 Silencing Different from Inhibition
Following observation of the Akt effects, we wished to determine
if Hsp70 siRNA, silencing expression of Hsp72, would act in a similar
manner to Hsp70 inhibition. This experiment could also demonstrate if
Hsp70 is not involved directly in the resistance machinery. Hsp70
siRNA increases Akt levels. Thus, if Hsp70 is not involved then the
increased Akt should enhance the resistance mechanisms compared
with the cells treated with a control non-silencing siRNA. To test this
hypothesis, TR-MCF7 cells were transfected with Hsp70 or control
siRNA.

Surprisingly,

the

data

supported

neither

hypothesized

outcome. Silencing of Hsp70 in the presence of 4-OHT had no impact
versus control siRNA. The cells were equally resistant (Figure 4.4A).
This data suggests that the observed mechanism is due in combination
to Akt reductions as well as loss of Hsp70 activity. Thus, increasing Akt
levels and increasing Hsp70 activity should promote a resistance
phenotype.

Generation of 4-OHT Resistance by Hsp70-activator
Previous work from our lab demonstrated that compounds which
enhance Hsp70 activity can preserve Akt levels (Koren et al., 2010).
This compound, SW02, increases Hsp70 ATP-hydrolysis rates as well
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as stabilizes Akt. SW02 was also shown to rescue the toxicity in cancer
cells observed following treatment with an Hsp70 inhibitor (see
Chapter 2). We pre-treated naïve MCF7 cells with 50µM SW02 prior to
application of 4-OHT to test if it could induce a resistance to 4-OHT.
Indeed, SW02 enhanced proliferation in the presence of 4-OHT
(Figure 4.4B). This finding, coupled with the Hsp70 silencing not
behaving like an Hsp70 inhibitor, suggests that, though necessary, Akt
is not alone in the generation of this particular resistance mechanism.
Hsp70 clearly plays a crucial role in the induction and maintenance of
resistance mechanisms.

Discussion
Here we define a strategy supporting the use of Hsp70 inhibiting
compounds for breast cancers refractory from aberrant Akt activity.
This outcome seems dependent on chaperone-mediated regulation of
Akt stability (Figure 4.5). While the effects on Akt cannot be solely
ascribed to the restoration of sensitivity to tamoxifen, the work
presented here strongly supports further investigation into depleting
total levels of all Akt members as a therapeutic strategy for breast
cancer and possibly other cancers driven by alterations in the
PI3K/PTEN/Akt pathway.

80

While other kinases have been identified to phosphorylated ERα
(Guo et al., 2010), Akt is a major survival kinase, regardless of
resistance phenotype, and its clearance could enhance the efficacy of
chemotherapeutics. If our hypothesis that YM-1 is an Hsp70 inhibitor is
accurate, this clearance could be due to enhanced ubiquitination of
Akt, as the ubiquitin ligase for Akt, CHIP (carboxy terminus of Hsc70
interacting protein)(Dickey et al., 2008), is known to interact with
Hsp70 (Qian et al., 2006).
There are comparisons to be made to the use of Hsp90 inhibitors
as a cancer therapy (Beliakoff and Whitesell, 2004). Hsp90 inhibitors
have also been used in clinical trials, but these have met with greater
success largely due to the discovery of geldanamycin, a natural
inhibitor of Hsp90, which guided many of the medicinal chemistry
approaches that have led to those now being tested in humans.
However, there is one feature of Hsp90 inhibitors that may ultimately
lead the downfall of this approach for cancer; the secondary induction
a heat shock response. Induction of heat shock proteins are prosurvival and can prevent apoptosis in some cancers (Afanasyeva et al.,
2007; Dudeja et al., 2009; Jiang et al., 2009; Kong et al., 2011). This
does not occur when Hsp70 is inhibited. In fact, the levels of inducible
Hsp70 are often slightly reduced compared to vehicle treatment
(Jinwal et al., 2009; Koren et al., 2010). Thus, while depletion of
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constitutive Hsp90 members may be less toxic than depletion of
constitutive Hsp70 members in general, inhibition of Hsp70 may
ultimately be more effective due to this non-specific consequence of
Hsp90 inhibition.
Despite these data supporting Hsp70 inhibition as a treatment
strategy for Akt-driven cancers, it is possible that Hsp70 inhibition will
cause toxicity in normal tissues when administered systemically. With
this

in

mind,

we

sought

to

determine

whether

a

separate

therapeutically-relevant application of Hsp70 inhibitors could be
identified that would reduce the potential for toxic side-effects. We
speculated that Hsp70 inhibitors could open the door for longer
intervals between treatments and reducing the likelihood for off-target
toxicities. In further support of this idea, Akt members, which are
primary targets of Hsp70 inhibition, are major players in the
generation of resistance to a number of therapeutics (Brognard et al.,
2001; Campbell et al., 2001; Clark et al., 2002; Sun et al., 2001).
Akt2 in particular is a primary kinase of ERα phosphorylation, a
modification that facilitates resistance to tamoxifen in MCF7 cells (Sun
et al., 2001). Interestingly, Akt2 was the most sensitive of the Akt
members to Hsp70 inhibition in these studies (see Ch.2: Figure 3A &
B).
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Here, we demonstrated that by incorporating our knowledge of
chaperone- and Akt-mediated resistance mechanisms, we were able to
determine the specific mechanism of action for the effects of YM1 in
MCF7 cells. Not only does this study show that brief treatments with
an Hsp70 inhibitor could be an effective strategy for restoring
sensitivity to compounds with known toxicity profiles, but also shows
that mechanisms can be used to define the efficacy of drugs.
Tamoxifen therapies typically fail due to the development of
resistance. Acquired resistances take time to develop. Our studies
have demonstrated that brief treatments with YM1 can re-sensitize
refractory cancers to tamoxifen. The benefit of such a short treatment
is the lack of opportunity for a resistance to YM1 itself as well as
reduced likelihood for off-target toxicities. Moreover, the ability to
negate existing resistances allows for the reintroduction of putative
chemotherapies; preventing the need for more costly and potentially
dangerous secondary and tertiary therapeutic strategies. These patient
benefits coupled with the high number of cancer varieties linked to Akt
dysfunction

provides

a

platform

for

the

continued

study

and

development of new compounds to deplete Akt through manipulation
of this Hsp70 inhibitor scaffold.
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Figure 4.1. TR-MCF7 cells and MCF7 cells susceptible to YM-1 toxicity at 48
hours but not at 4 hours; tamoxifen does not alter cytotoxicity. TR-MCF7 and
parental MCF7 cells were treated for 48 hours in with 10µM YM-1. After 48 hours,
media were collected and analyzed by LDH assay. Values shown are a % of vehicle
treatment ± SD (A). MCF7 cells were treated for 4 hours with 10µM YM-1. At 4
hours, medium was replaced with standard growth media for 44 hours. TR-MCF7
cells were treated with 10µM YM-1 for 4 hours. At 4 hours, the media was removed
and replaced with standard TR-MCF7 media containing 10µM 4-OHT or 95% EtOH,
the vehicle for 4-OHT, for 44 hours. After 48 hours from initial treatment, media
were collected and analyzed by LDH assay. Values shown are a % of vehicle
treatment ± SD (B).
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Figure 4.2. Brief exposure to YM-1 restores tamoxifen effect in resistant cell
model. TR-MCF7 cells were treated with 4-OHT for 48 hours, YM-1 (or vehicle) for 4
hours followed by 44 hours of either 4-OHT or 95% EtOH, or YM-1 (or vehicle) for 48
hours. At 48 hours from initial treatment, MTT viability assays were performed.
Viability values of each treatment as a % of 48 hours of 4-OHT treatment ± SD (A).
2-Way ANOVA analysis comparing all YM-1 treatment groups ( - 4-hour YM-1then
4-OHT, - 48 hour YM-1, - 4-hour YM-1 then 95% EtOH), revealed significance
across concentrations (F(2,30)=54.22, p<0.0001), and treatment strategy (F(4,
30)=41.04, p<0.0001), but no significant interaction (F(8,30)=1.83, p=0.1107). * indicates significant difference (p<0.05) of 4-hour YM-1 then 4-OHT from other two
groups with exception of 10µM treatments, significance as indicated (ns =
p>0.05)(B). 1-way ANOVA of YM-1 + 4-OHT strategy revealing significance of 10µM
concentration (F(4,10)=16.49, p=0.0002)(C). Analysis of YM-1 + 95% EtOH, by 1way ANOVA, revealed no significance across tested concentrations (F(4,10)=3.435,
p=0.0516)(D). 48-hour YM-1 treatment showed significance differences between all
concentrations and the 10µM concentration, by 1-way ANOVA (F(4,10)=12.32,
p=0.0007)(E). 1-way ANOVA analysis (F,(5,12)=24.33, p<0.0001) comparing all
10µM YM-1 treatments, 48-hour 4-OHT, and vehicle treatments revealed no
significant difference between 48-hour 4-OHT and both 4-hour 10µM YM-1 + 95%
EtOH and 48-hour 10µM YM-1 treatments; whereas the 48-hour 4-OHT and the 4hour 10µM YM-1 + 95% EtOH were significantly different from the 4-hour YM-1 + 4OHT treatment (p<0.05)(F).
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Figure 4.3. Phosphorylation but not localization of Estrogen Receptor α
altered by YM-1. TR-MCF7 cells were treated with indicated conditions for 4 hours.
Nuclear isolates and cytosolic fractions were compared by Western blot,
representative blots shown (A & C). Densitometry analysis of pERα and ERα levels
displayed as % of vehicle treatment ± SD (B & D).
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Figure 4.4. Hsp70 siRNA does not alter resistance; tamoxifen resistance
induced by Hsp70 ATPase activator. TR-MCF7 cells were transfected with nonsilencing control or Hsp72 siRNA. 48 hours after transfection, cells were grown in
medium containing vehicle (95% EtOH), 5µM, or 10µM 4-OHT. 48 hours after 4-OHT
addition cells were simultaneously fixed and stained with 0.1% Crystal violet solution
in 30% methanol. Crystal violet was released from cells by addition of 10% acetic
acid. Acetic acid solution was collected and analyzed on spectrophotometer as
measure of relative percent growth (A). MCF7 cells were treated with 50µM of an
Hsp70 activator, SW02, or vehicle (DMSO) for 24hrs. Medium was then changed to
new medium supplemented with 10µM 4-OHT for 48 hours. 48 hours after 4-OHT
addition, cells were fixed, stained and analyzed as above. Relative percent growth as
measured by spectrophotometer ± S.D. (white bar, DMSO; gray bars, SW02)(B).
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Figure 4.5. Model for predicted re-sensitization pathway following Hsp70
inhibition. Depicted are two accepted pathways for ERα transcriptional regulation,
either in the presence of estradiol or via an alternative, Akt dependent, mechanism
in the presence of the anti-estrogen, 4-OHT. The addition of an Hsp70 inhibitor –
compounds having now been demonstrated to reduce Akt – prevents the
phosphorylation of ERα by Akt. Thus, Hsp70 inhibition leads to a reacquisition of
sensitivity to 4-OHT.
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Chapter 5: Conclusions

In this study, we have illustrated the regulation of the
chaperone/client

relationship

and

how

this

relationship

can

be

manipulated to produce a variety of outcomes. Here, we have shown
that Hsp70 ATPase inhibitors can produce cytotoxicity in breast cancer
cell models. These compounds not only inhibit Hsp70 but also clear
Akt. This Akt clearance is dependent on Hsp70 levels and can be
rescued with Hsp70 activating compounds. We also demonstrated that
brief treatment with an Hsp70 ATPase inhibitor can facilitate the
overcoming of resistance to tamoxifen in a tamoxifen resistant breast
cancer cell line and that this resistance can be generated using an
Hsp70 activator.
The molecular chaperone Hsp70 has long been implicated as a
prosurvival factor in human cancers. Recently, work has focused on
the anti-cancer potentials of Hsp70 inhibitors (Evans et al., 2010; Leu
et al., 2009; Leu et al., 2011; Powers et al., 2010) and genetic
silencing of the cytosolic Hsp70 family members (Guo et al., 2005;
Havik and Bramham, 2007; Powers et al., 2008). Beyond the direct
prosurvival abilities of Hsp70, it has been demonstrated that Hsp70
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regulates the function and stability of other prosurvival proteins. The
use of these crude Hsp70 ATPase inhibitors demonstrates the high
potential these compounds and backbones possess. In cells facing high
metabolic and proteostatic demands, Hsp70 and its family members
are crucial elements that, once inhibited, can be targeted readily with
seemingly

little

insult

to other

“normal”

cell types.

Here, we

demonstrated that multiple classes of Hsp70 inhibitors all produce
reductions in Akt as well as cancer cell exclusive cytotoxicity.
These studies remain inconclusive due to mechanistic difficulties
brought about by the nature of the Hsp70/Hsc70/Akt relationship. We
demonstrate that the action of these compounds is reduced in the
absence of Hsp70. However, we recognize that Hsc70 is also a likely
target; especially since the interactions of MB and rhodacyanines have
been shown with Hsc70 but not Hsp70 (Jinwal et al., 2009; Rousaki et
al., 2011). The unfortunate limitation with examining this further is the
induction of Hsp70 observed following Hsc70 silencing. In order to
effectively show that the toxicity and Akt effects are dependent on the
cytosolic Hsp70 chaperones we would have to silence both Hsp70 and
Hsc70. This strategy carries a large pitfall in that dual silencing of both
cytosolic Hsp70 members results in cell death (Powers et al., 2008).
Thus, we could not properly demonstrate in a cell model the exact
mechanism of these compounds; though we do acknowledge the
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likelihood of pluripotent mechanisms playing a role in the observed
data.
We were also unable to elucidate the exact mechanisms behind
the overcoming of resistance phenomena. The literature suggests
some evidence that supports how, beyond the Akt aspects explored by
our group, inhibition of Hsp70 can lead to changes in ERα activity. It
has been shown that Hsc70 can bind to an unliganded ERα and
abrogating activity (Ogawa et al., 2005). Low levels of Hsp70 were
found to improve the effectiveness of aromatase inhibitors in patients,
a therapy to block estrogen production (Yiu et al., 2010). However,
silencing of Hsp70 did not alter the behavior of 4-OHT-resistant MCF7
cells to 4-OHT. This was interesting since silencing of Hsp70 increases
Akt levels. Our hypothesis was that the absence of Hsp70 could
perhaps alter the resistance phenotype similar to the use of the Hsp70
inhibitors; or would increase in Akt levels and thus drive the resistance
mechanisms producing, again, an altered phenotype. Neither of these
outcomes was validated by the data. This suggested to us that it was
not only the absence of Hsp70 activity but also the reduction in Akt
levels that produced the overcoming of resistance.
While more work needs to be done to validate the mechanisms
and specific targets of these compounds, there is much that can be
taken away from these studies. The ability of two highly homologous
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compounds, Hsp70 and Hsc70, to regulate a single client in such
dramatically opposite ways deserves further study. The area most
distinct between Hsp70 and Hsc70 are in the substrate binding domain
with a 31% difference (Callahan et al., 2002). If we were to
understand the relationship between which clients preferred which
chaperone in relation to the cellular environment it would then be
possible to selectively target just one of the Hsp70 family members to
clear an aberrant client.
This option of selective targeting of a chaperone would be a step
forward from the current work being conducted on Hsp90 inhibitors.
Though Hsp90 inhibitors have demonstrated success in the lab and
clinical trials (Beliakoff and Whitesell, 2004; Hostein et al., 2001; Modi
et al., 2007; Pacey et al., 2010; Pacey et al., 2011; Rajan et al., 2011)
they could be improved upon. Hsp90 inhibitors have the unfortunate
effect of causing an induction of the other stress-inducible heat shock
genes. As mentioned throughout this manuscript, many of the
inducible heat shock genes are anti-apoptotic and are often linked to a
negative prognosis in cancer (Dudeja et al., 2009; Garrido et al.,
2003; Jiang et al., 2009; Rashmi et al., 2004; Sliutz et al., 1996;
Vargas-Roig et al., 1997; Vargas-Roig et al., 1998; Yano et al., 1996).
While Hsp90 regulates numerous oncogenic and prosurvival clients,
the act of induction, increasing Hsp72 levels, following Hsp90 inhibition
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abrogates the ability of Hsp90 inhibitors in cancer cells. In fact, this
issue has been addressed in the literature demonstrating increased
Hsp90 inhibitor efficacy under conditions depleting Hsp72 (Bagatell et
al., 2000; Davenport et al., 2010; Guo et al., 2005). Another related
strategy could be to inhibit the heat shock response via heat shock
factor (HSF) regulation (Whitesell and Lindquist, 2009). This would
lead to no induction of stress response proteins following Hsp90
inhibition; a result similar to Hsp72 depletion.
There is another class of heat shock protein which could provide
new targets for cancer therapy; the 40-kDa heat shock proteins, or
Hsp40. Hsp40s, or J proteins, have a highly conserved ≈70 amino acid
region, the J domain (Kampinga and Craig, 2010). These J proteins are
thought to present Hsp70 with client proteins as well as stimulate ATP
hydrolysis (Johnson and Craig, 2001). If true, and there is a J protein
that has specificity for Akt, or any oncogenic client protein, it could be
possible to determine what governs the J protein/Akt relationship and
perhaps then promote that interaction to clear specifically Akt.
Hsp70 is a vital target in the treatment of cancer. Understanding
client processing under distinct environmental conditions could lead to
advanced therapeutics channeling specific client proteins to specified
fates. The use of Hsp70 inhibitors could also be used in combination
with Hsp90 inhibitors and with other chemotherapies known to induce
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Hsp72. All of these strategies, along with the search for more potent
inhibitors, increase our knowledge of how the molecular chaperone
pathways affect disease, not only cancer, but any disease involving
aggregation, preserved mutation, or aberrant function. Eventually, we
may be able to manipulate the chaperone network in a manner to
target a distinct client protein. This makes the future of Hsp70, and
the rest of the molecular chaperones, very exciting; especially
considering the dependence of cancer cells on the Hsp70 family.
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Appendix A (continued)

Figure A1. In-Cell-Western Standard Curve. HeLa cells were plated at 40%
confluency in 96-well plates and transfected with Akt or control siRNA for 72 hours.
Akt antibody was applied at indicated dilutions. Akt knockdown was detectable down
to a 1:800 dilution. GAPDH (green) was used to estimate toxicity and cell adhesion.
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Appendix A (continued)

Figure A2. Overexpression of Hsp70 enhances MB and AC clearance of Akt.
HeLa cells were transfected with Myc-Hsp70 or empty vector, cells were then treated
in increasing doses with Hsp70 ATPase inhibitors methylene blue (MB) and Azure C
(AC); experiments were analyzed by Western Blot (A).
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